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Nanoparticle based therapeutics have been successfully used in the treatment of
breast cancer. Development of nanovectors targeted to cancer cells or elements in the tumor
microenvironment has been pursued to improve their site specific accumulation while
reducing the non-specific delivery to normal tissues. However, addition of targeting ligands
to the surface of nanovectors while maintaining their payload carrying potential is generally
challenging. Therefore, there is a critical need to develop surface decoration strategies that
allow for effective combination of targeting and payload delivery to the tumor.
In this study, we propose a novel strategy for covering the surface of mesoporous
silicon particles (S1MP) with targeting entities (bacteriophage) and gold nanoparticles
(AuNP) while maintaining their payload carrying potential. Retention of payload carrying
potential after the formation of BASP was demonstrated by loading different types of
nanoparticles and macromolecules into the porous structure of S1MP. Additionally, the
BASP displayed enhanced near infrared (NIR) absorbance that could be used for thermal
ablation of the tumor as well as for in vivo monitoring using NIR surface enhanced Raman
spectroscopy (NIR-SERS). In vitro targeting studies under static and shear flow conditions,
as experienced in healthy microvasculature (100s-1), did not display significant targeting
vi

efficiency of the CRKL targeted BASP. However, in shear rates relevant to the tumor
microvasculature (10s-1), CRKL targeted BASP demonstrated 2-fold higher adhesion than
S1MP to endothelial cells. These results were further exaggerated in in vivo conditions
evidenced by intravital microscopy studies that showed up to 4 fold increase in the number of
CRKL targeted BASP accumulating in the tumor vasculature compared to both S1MP and
fd-tet non-targeted BASP. In vivo experiments also showed that BASP maintain their
integrity following intravenous administration in mice and a 3-fold higher tumor
accumulation than S1MP. Furthermore, treatment of breast tumor bearing mice with
Abraxane loaded CRKL targeted BASP showed significantly reduced tumor growth in
comparison to Abraxane or Abraxane loaded S1MP controls. Overall, this study
demonstrates a simple and efficient strategy to target S1MP to breast cancer while
maintaining their ability to carry large amounts of therapeutic payload.

vii

Table of Contents
Dedication ............................................................................................................................... iii
Acknowledgements ................................................................................................................ iv
Abstract.................................................................................................................................... v
List of illustrations ............................................................................................................... xiii
List of Tables ......................................................................................................................... xv
CHAPTER 1: INTRODUCTION.......................................................................................... 1
1.1

Breast cancer as a disease ........................................................................................ 1

1.1.1

Pathophysiology ................................................................................................ 1

1.1.2

Current therapeutic strategies for breast cancer ........................................... 2

1.1.3

Disavantages of conventional chemotherapy ................................................. 4

1.2

Nanomedicine research and its application in breast cancer ............................... 4

1.2.1

What is nanomedicine?..................................................................................... 4

1.2.2

Advantages of nanovectors............................................................................... 5

1.2.3

Nanotechnology in breast cancer ..................................................................... 6

1.2.4

Limitations of currently investigated nanovectors ........................................ 8

1.3

Multistage nanovectors .......................................................................................... 10

1.3.1

Rational design ................................................................................................ 10

1.3.2

S1MP ................................................................................................................ 12

viii

1.3.3

S2NP ................................................................................................................. 14

1.3.4

Challenges in designing molecularly targeted MSV .................................... 16

1.4

Targeting vascular zipcodes with bacteriophage ................................................ 17

1.4.1

Filamentous bacteriophage and phage display ............................................ 17

1.4.2

Identification of targeting ligand – CRKL binding peptide........................ 19

1.4.3

AuNP-bacteriophage networks ...................................................................... 22

1.5

Hypothesis ............................................................................................................... 23

1.6

Significance ............................................................................................................. 25

1.7

Objectives ................................................................................................................ 25

CHAPTER 2: MATERIALS AND METHODS ................................................................ 26
2.1

Identification and evaluation of CRKL expression in in vitro, in vivo and

clinical samples .................................................................................................................. 26
2.1.1

Cell culture ...................................................................................................... 26

2.1.2

Tumor models.................................................................................................. 27

2.1.3

Patient samples ................................................................................................ 27

2.1.4

Evaluation of surface bound CRKL by flow cytometry .............................. 28

2.1.5

Assessment of cellular localization of CRKL using immunofluorescence . 28

2.1.6

Evaluation of CRKL expression in tumor using immunohistochemistry

and immunofluorescence .............................................................................................. 29
2.2

Nanovector design and fabrication ....................................................................... 29
ix

2.2.1

S1MP fabrication ............................................................................................ 29

2.2.2

AuNP synthesis ................................................................................................ 30

2.2.3

Bacteriophage isolation .................................................................................. 31

2.3

Assembly of Bacteriophage Associated Silicon Particles (BASP) ...................... 31

2.4

Characterization of BASP ..................................................................................... 32

2.4.1

Visualization of BASP formation .................................................................. 32

2.4.1.1 Confocal microscopy..................................................................................... 32
2.4.1.2 Transmission Electron Microscopy............................................................... 32
2.4.1.3 Scanning Electron Microscopy ..................................................................... 32
2.4.2

Effect of porosity and zeta potential of S1MP on BASP formation ........... 33

2.4.3

Evaluation of contact angle ............................................................................ 33

2.4.4

Spectral characteristics of BASP ................................................................... 33

2.4.5

Thermal effects of BASP ................................................................................ 34

2.5

In vitro degradation of BASP ................................................................................ 34

2.6

Loading of S2NP ..................................................................................................... 35

2.7

In vitro studies ......................................................................................................... 36

2.7.1

Evaluation of cellular association of BASP .................................................. 36

2.7.2

Evaluation of interaction with endothelial cells under shear stress ........... 38

2.8

In vivo studies.......................................................................................................... 38

x

2.8.1

Evaluation of targeting efficiency of CRKL targeted BASP ...................... 38

2.8.2

Evaluation of therapeutic efficacy of CRKL targeted BASP...................... 39

2.8.3

Intravital microscopy for studying particle flow characteristics ............... 39

2.9.1

Collection of conditioned media (CM) for evaluation of secreted CRKL . 40

2.9.3

Collection of patient serum samples .............................................................. 40

2.9.4

Evaluation of soluble fraction of CRKL by Enzyme Linked

Immunosorbant Assay .................................................................................................. 41
CHAPTER 3: RESULTS ..................................................................................................... 42
3.1

CRKL as a cell surface biomarker ....................................................................... 42

3.1.1

Localization on cell surface ............................................................................ 42

3.1.2

Expression in in vivo and clinical tumor biopsies ........................................ 45

3.2

Physical characterization of BASP ....................................................................... 48

3.2.1

Assembly of BASP........................................................................................... 48

3.2.2

Effect of porosity and zeta potential of S1MP on BASP formation ........... 52

3.2.3

Evaluation of BASP contact angle ................................................................. 56

3.2.4

Spectral characteristics of BASP ................................................................... 57

3.2.5

Heating efficiency of BASP ............................................................................ 59

3.3

Loading efficiency of BASP ................................................................................... 60

3.3.1

Superparamagnetic iron oxide nanoparticles .............................................. 60

3.3.2

Quantum dots .................................................................................................. 62
xi

3.3.3
3.4

BSA-FITC loading .......................................................................................... 64

Biodegradation of BASP ........................................................................................ 64

3.4.1

In vitro degradation......................................................................................... 64

3.4.2

In vivo integrity ............................................................................................... 66

3.5

In vitro targeting efficiency of BASP .................................................................... 68

3.5.1

Static conditions .............................................................................................. 68

3.5.2

Effect of shear stress ....................................................................................... 72

3.6

In vivo targeting efficiency ..................................................................................... 74

3.7

Therapeutic efficacy ............................................................................................... 77

3.8

CRKL as a soluble biomarker............................................................................... 78

3.8.1

Evaluation of soluble CRKL in in vitro and in vivo samples ....................... 78

3.8.2

Evaluation of soluble CRKL in clinical samples .......................................... 78

CHAPTER 4: DISCUSSION ............................................................................................... 81
CONCLUSIONS AND FUTURE DIRECTIONS .............................................................. 90
REFERENCES...................................................................................................................... 92

xii

List of Illustrations

Figure 1: Schematics of breast cancer. ................................................................................. 2
Figure 2: Sequential biological barriers ............................................................................... 9
Figure 3: Tailoring geometry and porosity of S1MP.. ....................................................... 13
Figure 4: S2NP loading into S1MP...................................................................................... 15
Figure 5: Loading of S1MP with SPION. ........................................................................... 16
Figure 6: Bacteriophage structure and phage display....................................................... 18
Figure 7: A working model based on the switchblade integrin activation. ..................... 21
Figure 8: Schematic illustrating the electrostatic interaction of AuNP and
bacteriophage. ....................................................................................................................... 23
Figure 9: Schematic presentation of (A) Bacteriophage Associated Silicon particles. ... 24
Figure 10: Surface localization of CRKL in breast cancer cells in vitro. ......................... 44
Figure 11: CRKL expression in in vivo samples and clinical tumor biopsies.................. 46
Figure 12: Co-localization of CRKL and tumor associated vasculature. ........................ 47
Figure 13: Visualization of the BASP formation. .............................................................. 50
Figure 14: Effect of concentration and order of incubation on the formation of BASP 52
Figure 15: BASP design- effect of S1MP geometry and porosity.. ................................... 53
Figure 16: Effect of surface zeta potential of S1MP on BASP formation........................ 55
Figure 17: Contact angle measurements of BASP ............................................................. 56
Figure 18: UV-Vis spectra of BASP. ................................................................................... 57
Figure 19: Detection of BASP using NIR-SERS ................................................................ 58
Figure 20: Temperature as a function of NIR laser exposure time of AuNP and BASP 59
xiii

Figure 21: Loading of SPION into BASP. .......................................................................... 61
Figure 22: Loading of quantum dots into BASP.. .............................................................. 63
Figure 23: Time dependent degradation of S1MP and BASP in 100% FBS. ................. 65
Figure 24: In vivo integrity of BASP.. ................................................................................. 67
Figure 25: Association of BASP with cells in vitro under static conditions.. ................... 69
Figure 26: Association and internalization of BASP in MCF7 cells. ............................... 72
Figure 27: Effect of shear stress on the adhesion of CRKL targeted BASP. .................. 73
Figure 28: BASP accumulation in breast tumor models. .................................................. 75
Figure 29: Speed of particles flowing through the tumor vasculature ............................ 76
Figure 30: Therapeutic efficiency of Abraxane loaded BASP.. ........................................ 77
Figure 31: Assessment of secreted CRKL levels ................................................................ 80

xiv

List of Tables

Table 1: List of therapeutic agents used in clinic/under clinical trials for breast cancer…......3
Table 2: List of nanovectors clinically approved/under clinical trials for the use of breast
cancer therapy……………………………………….……………………………………….8
Table 3: Relationship between CRKL expression and clinicalpathological parameters……48

xv

CHAPTER 1: INTRODUCTION

1.1

Breast cancer as a disease

1.1.1

Pathophysiology
The structure of the female breast is complex – comprising of (i) milk producing

glands called lobules, (ii) ducts that carry milk from the lobules to the nipple and (iii) stroma
that is made up of connective tissue, blood vessels and lymphatic vessels (Figure 1). Breast
cancer is a disease where cells in the breast divide and grow without normal control.
Depending on the location of the tumor, breast cancer can be lobular or ductal. These can be
further divided into invasive and non-invasive carcinoma. About 70 – 80% of breast cancers
are invasive ductal carcinomas. A third type of cancer is inflammatory breast cancer where
the cancer cells block the lymph vessels, causing redness and warmth in the breast. Breast
cancers are staged according to the TNM staging given by the American Joint Committee on
Cancer (AJCC), based on their tumor size (T), nodal involvement and size (N) and metastatic
involvement (M). This staging is very important in deciding the overall prognosis and the
treatment of patients. Staging is done by a combination of physical examinations, various
imaging tests, such as x-ray and computed tomography (CT) scan, blood tests and biopsies.
In spite of advancements in detection techniques, breast cancer is the second leading cause of
cancer related deaths in women in the US [1]. Early detection techniques and primary tumor
treatments have markedly improved, however occurrence of distant metastasis and the
inefficiency in their treatment make breast cancer the second leading cause of cancer related
death in women in the U.S. [2].
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Figure 1:: Schematics of breast cancer. Top row, lobular carcinoma and bottom row, ductal
carcinoma.

Adapted

from

the

website

of

the

National

Cancer

Institute

(http://www.cancer.gov)
1.1.2

Current therapeutic
eutic strategies for breast cancer
Depending on the TNM staging the schedule of therapy varies. The first line therapy

in breast cancer includes surgery, radiation therapy, cytotoxic chemotherapy, hormone
therapy and targeted molecular therapy [3]. Surgery is usually prescribed when the tumor is
localized and has defined margins. Radiation therapy typically followss surgery to help lower
the chance of recurrence in the breast or nearby lymph nodes
nodes.. Radiation is also the choice of
treatment when distantt metastase
metastases are seen. Chemotherapy is the treatment using cytotoxic
drugs either injected intravenously or given orally. The most common cytotoxic
c
chemotherapeutic drugs used in breast cancer include anthracyclines (Doxorubicin), taxanes
taxane
(Paclitaxel) and platinum compounds (Cisplatin) among others. Nanoparticle formulations of
doxorubicin (Doxil®)[4] and paclitaxel (AbraxaneTM)[5] have also been successfully used in
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the clinic for breast cancer therapy for many years now. Molecularly targeted therapeutic
agents based on identified biomarkers are also used in combination with chemotherapeutic
drugs. Examples include Herceptin® [6], a monoclonal antibody which interferes with
overexpressed HER2 thereby inhibiting the cell proliferation caused by HER2. Another
example is Lapatinib [7], a synthetic tyrosine kinase inhibitor that affects HER2 and
epidermal growth factor receptor (EGFR) pathways. Table 1 lists therapeutic agents that are
either clinically approved or under clinical trials.
Therapeutic agents currently used in the clinic
Chemical name Brand name Type
Trastuzumab
Herceptin
Monoclonal antibody
Lapatinib
Tykerb
Drug
Bevacizumab
Pertuzumab

Avastin
Perjeta

Everolimus
T-DM1

Afinitor
Kadcyla

Monoclonal antibody
Monoclonal antibody

Drug
Monoclonal antibody/drug
conjugate
Therapeutic agents under clinical trials
Name
Phase
Type
AUY922
Phase I,II
Drug
BEZ235
BGT226

Phase I
Phase I,II

Drug
Drug

PF-04691502

Phase II

Drug

XL765

Phase I,II

Drug

BKM120
GDC-0941
MK-2206
CDX-011

Phase I
Phase I,II
Phase I
Phase II

Mode of action
HER-2/neu inhibitor
Tyrosine kinase
inhibitor
Angiogenesis inhibitor
Prevents HER-2
dimerization
mTOR inhibitor
HER-2/neu inhibitor
Antimitotic
Mode of action
Heat Shock Protein 90
inhibitor
PI3 kinase inhibitor
PI3 kinase/mTOR
inhibitor
PI3 kinase/mTOR
inhibitor
PI3 kinase/mTOR
inhibitor
PI3 kinase inhibitor
PI3 kinase inhibitor
Akt inhibitor
Antimitotic

Drug
Drug
Drug
Monoclonal antibody/drug
conjugate
Table 1: List of therapeutic agents used in clinic/under clinical trials for breast cancer.
Source www.clinicaltrials.gov.
3

1.1.3

Disavantages of conventional chemotherapy
Conventional chemotherapeutic as well as targeted antibody molecules, when injected

into the blood stream, either get degraded or sequestered by the reticuloendothelial system
(RES). Further, owing to their small size, they easily penetrate the endothelial barrier and
non-specifically enter the tissue space in any organ, leading to undesired cytotoxic side
effects in uninvolved organs, such as hypersensitivity reactions (Paclitaxel) and
cardiotoxicity (Doxorubicin) [8]. Thus, the probability of a drug molecule reaching the target
site is as low as 1 in 100,000 molecules [9]. Due to the inefficiency of conventional
chemotherapy and the low quality of life experienced by patients, better alternatives had to
be identified. Nanomedicine showed promising results in improving both the quality and
efficiency of treatments.
1.2

Nanomedicine research and its application in breast cancer

1.2.1

What is nanomedicine?
Nanomedicine is the field of medicine that employs materials that are themselves or

have components in the nanoscale, i.e. 1 to 1000nm. Both designing nanovectors for delivery
of diagnostic and therapeutic agents as well as precise patterning of surfaces are subfields of
nanomedicine [10]. Owing to the small size of these nanovectors, their interactions with
biological systems at the molecular level are unique. Various nanovectors have been
developed for use in cancer detection, diagnosis, imaging, treatment and disease monitoring.
Nanovectors may be made from a spectrum of materials including lipids, phospholipids,
dextran, carbon, silica, gold and silver [11], among others. Nanovector design has evolved
over the years. The first generation of nanovectors were generally composed of a single class
of particles (liposome, micelle, etc.) encapsulating a payload and accumulates in the tumor
4

due to enhanced permeation and retention (EPR) effect. The accumulation of such
nanovectors in the tumor cells solely depend on their size [12]. The second generation of
nanovectors encompasses delivery systems with added functionalities such as decoration of
the nanovector surface with targeting moieties for active targeting and active/triggered
release of payload at site of action [13]. Active targeting refers to the biomolecular
recognition of cancer cell surface epitopes by recognition moieties on nanovector surfaces,
such as antibodies, peptides or aptamers. Contemporary nanovectors are more complex and
may employ multiple classes of nanoparticles that are designed to perform distinct functions
[13].
1.2.2

Advantages of nanovectors
Unlike conventional chemotherapeutic drugs that are small molecules able to cross

most endothelial barriers and reach the tissue beyond, nanovectors are large enough to avoid
transmigration across normal endothelial barrier, but small enough to “leak” through
fenestrations in the tumor vasculature and concentrate in the tumor tissue [10]. The ability of
nanovectors to carry substantial amounts of therapeutic agent to the intended site is the major
advantage over conventional cytotoxic/immunotargeted drugs, whereas the chance of a drug
molecule reaching the tumor site is only 1 in 100,000 [10]. Another important advantage of
nanovectors is their protective effect on the payload. The first barrier faced by intravenously
injected drugs or siRNA or monoclonal antibodies is degradation. Encapsulation of the
therapeutic agent in nanoparticles protects the active ingredient from such degradation, until
they reach the disease site. This protection of drug indirectly translates to minimized
interaction with normal tissues by virtue of size exclusion, thereby reducing unwanted side
effects [8]. While intravenously administered free drug molecules get cleared from the
5

plasma either through the kidneys (hydrophilic molecules [14]) or through enzymatic
metabolism in the liver (lipophilic molecules [15]), larger nanovectors (< 15 nm is the renal
cut off [16]) do not get cleared by the renal system quickly as well as protect the active
ingredient from enzymatic metabolism in the liver [17] .
Many cancer chemotherapies rely on combination therapy, i.e. co-administration or
sequential administration of multiple drugs, to overcome resistance and enhance the
therapeutic efficacy. Multidrug encapsulation in nanoparticles has been demonstrated in
various studies. Examples include doxorubicin loaded liposomes covered by layers of siRNA
loaded poly-L-lysine films for the treatment of triple-negative breast cancer [18] and
liposome encapsulated formulation of irinotecan and floxuridine for solid tumors [19]. This
enhances the probability of 2 individual drugs reaching the same tumor site than when
injected as free drug molecules [20].
Formulation of nanoparticles can be altered to facilitate sequential release of drugs, if
required. For example, the biodegradability of most materials used in the design of
nanovectors, facilitate the release of the payload after degradation [21]. Other approaches
include pH [22] and/or heat triggered [23] release of the active ingredient. Nanoparticles are
also beneficial due to their ability to penetrate cell membranes through receptor mediated
endocytosis and lysosomal escape after endocytosis [24] thereby facilitating the release of
drug directly inside the cells to enhance therapeutic effect.
1.2.3

Nanotechnology in breast cancer
Nanotechnology has made major contributions in breast cancer. Liposomal

doxorubicin (Doxil®) was the first and representative nanovector that was approved for
clinical use about two decades ago for Kaposi’s sarcoma [25]. Now they have also been used
6

in breast [26; 27] and ovarian cancer [28]. Nanoparticle albumin-bound paclitaxel, Abraxane,
is another drug that has been approved for metatstatic breast cancer therapy [29; 30]. There
are a few more nanovectors that are undergoing clinical trials for the treatment of breast
cancer, such as paclitaxel incorporating micelles [31] and TNF-bound colloidal gold
(Aurmine) [32; 33]. A list of nanovectors clinically approved/under clinical trials for use in
breast cancer therapy are summarized in Table 2. Other nanoparticle formulations for breast
cancer therapy that are still under pre-clinical evaluation include polymeric nanoparticle
encapsulating tamoxifen [34], adenovirus type 5 E1A (against ERBB2) [35], p53 loaded
nanoparticles [36] and nanoparticle-siRNA complexes directed to Ras [37].
Nanoparticles have also been used for various other applications in breast cancer. Use
of nanoparticles such as carbon nanotubes (CNT) [38], silicon nanowires (SiNW) [39],
quantum dots [40], gold nanoparticles [41] and silver nanoparticles ex vivo has allowed rapid,
label free, multiplexed detection of biomarkers at ultralow detection limits, which can
contribute substantially to the early diagnosis and accurate prognosis of cancers [42]. In vivo
tumor imaging using nanoparticles is also a very fast developing field of research. Magnetic
nanoparticles such as superparamagnetic iron oxide nanoparticles (SPION) and bismuth
sulfide nanoparticles [43] are attractive systems as they can be used as MRI contrast agents.
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Therapeutic agent
Doxorubicin

Type
Liposomal

Paclitaxel

Magnetic targeted
beads
Abraxane

siRNA against PLK1
gene product
Tumor Necrosis Factor
Cytarabine
Annamycin

Polymeric micelles
Synthetic
phospholipids and
cholesterol
Stable Nucleid Acid
Lipid Particles
(SNALP)
Colloidal gold
Liposomal
Liposomal

Clinical phase
Approved and in
clinical trials
Phase I,II

Indication
Breast cancer

Approved and in
clinical trials
Phase IV
Phase II

Breast cancer

Phase I

Liver metastasis

Liver metastasis

Breast cancer
Breast cancer

Phase 0
Phase II
Phase II

Breast cancer
CNS metastasis
Anthracycline
resistant breast
cancer
Docetaxel
Liposomal
Phase I
Advanced breast
cancer
Table 2: List of nanovectors clinically approved/under clinical trials for the use of breast
cancer therapy. Source www.clinicaltrials.gov.

1.2.4

Limitations of currently investigated nanovectors
Inspite of all the advantages described in Chapter 1.2.2, other than the few

nanovectors described above, no new nanovectors have been approved for clinical use in the
last two decades. There are various challenges that need to be addressed to enable the design
of more efficient nanovectors. Delivery of nanovectors to the tumor tissue faces various
obstacles from the site of injection until they reach the tumor tissue. Some of the barriers
include but are not limited to enzymatic degradation, recognition and sequestration by
reticulo-endothelial system (RES) and vascular endothelium (Figure 2).
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Figure 2: Sequential biological barriers experienced by a drug molecule or nanoparticle
when in circulation from the point of injection to the tumor site. Reproduced with permission
from [44].

Each of these barriers has to be overcome before the nanovector can efficiently
deliver therapeutics to the tumor cells. Many strategies have been put forward for
overcoming some of these barriers [45; 46]. For example, molecular targets on tumor cells
have been used to advantage for homing nanoparticles to the tumor site. Various peptide
[47], antibodies [48; 49], oligonucleotides [50; 51] and other molecules [52; 53] have been
conjugated to the surface of nanoparticles to enhance tumor specific accumulation. However,
the limited access of nanoparticles to the blood vessel walls diminishes the effectiveness of

9

the targeting moiety in enhancing nanoparticle accumulation in the tumor [54]. Another
technique used for increasing tumor accumulation is the conjugation of polyethylene glycol
(PEG) to the surface of nanoparticles, to delay or avoid their sequestration by the RES
organs. PEGylation prevents opsonization of the particles by immune cells, thereby
increasing the circulation time and chance for the nanovectors to accumulate in the tumor
[55]. PEGylation, however, masks targeting moieties conjugated on nanoparticles, thus
negating the advantage of targeting moieties [56]. Thus, we can understand that adding
functionalities to a single nanoparticle doesn’t solve the limitations. There is an emerging
requirement for a multimodular nanoassembly, in which different components with
individual and distinct functions act in a synergistic manner to circumvent each barrier
sequentially.
1.3

Multistage nanovectors

1.3.1

Rational design
A nanovector must be able to travel from the site of injection to the tumor site after

bypassing sequential biobarriers mentioned earlier. A single nanoparticle would not be able
to overcome all of the barriers successfully. Thus far, tumor specific accumulation of
nanoparticles has relied on EPR effect. This limits the versatility of nanoparticles in various
ways. First, the size of the particles is limited to the size of fenestrations present in the tumor
vasculature (380 – 780 nm) [57]. Most current nanovectors are approximately in this size
range (100 – 300 nm) and hence have been shown to extravasate through the fenestrations
and accumulate in the tumor mass [57]. Even this is not a constant feature as the size of the
fenestrations depends on the stage and type of tumors [58]. To address these issues, the
concept of multistage vectors (MSV) was developed [59]. MSV were designed as vasculature
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targeting nanovectors (Stage 1 MicroParticles, S1MP) that can release smaller payloads
(Stage 2 NanoParticles, S2NP) containing imaging/therapeutic agents. They were engineered
to overcome biological barriers by decoupling the multiple functions typically required by
nanovectors and distributing them onto multiple stages [21].
Most of the nanoparticles that are currently in the clinics or under investigation are
synthesized using bottom-up fabrication or self-assembly technique and hence acquire an
energetically favorable spherical shape. However, when in circulation, it has been shown that
the size and shape of particles affect their trajectory as well as specific (ligand-receptor type)
and non-specific (van der Waals, electrostatic and steric) interactions with the vessel wall
[60]. The size of the particles dictates their interaction with the red blood cells in the
circulation. Smaller nanoparticles (<500nm) stay in the middle of blood vessels because they
“fit” in the pockets between RBCs, while larger particles (micron sized) get pushed to the
“cell-free” zone of blood vessels by RBCs [54]. This process of “margination” has two main
functions: (1) it facilitates the “drift” of particles from the center of the vessel to the vessel
wall thereby (2) allowing higher probability of interaction of the particles with the
endothelial cells to “identify and bind” to molecular targets [60]. Spherical particles require
an external force, such as gravitational or magnetic, to induce a lateral shift/margination
towards the vessel wall [61]. On the other hand, non-spherical particles, depending on their
orientation in the circulation and the forces exerted by the blood on them, easily marginate
without the requirement of additional forces. The velocity with which the particles marginate
is directly proportional to their aspect ratio. Thus, spherical particles, with aspect ratio of 1
have the least propensity of marginating while discs (aspect ratio of infinity) have the highest
chance and velocity of marginating to the vessel walls [60].
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Another important aspect affected by the shape and size of the particles is their ability
to adhere to the vessel wall, following margination. As mentioned before, the interaction with
the vessel wall can be specific due to ligand-receptor interactions or non-specific, caused by
various physical forces. In both cases, the stronger these interactions are, the more force will
be required to dislodge the particles. Non-spherical particles, again, depending on their
orientation on the vessel wall, can have higher surface area interacting – both specific and
non-specific. This means, that the force required to dislodge the particle will be more than if
a spherical particle of similar volumes were to interact with the surface [60].
1.3.2

S1MP
Based on the above, our group rationally designed non-spherical S1MP that are made

of porous silicon S1MP. Porous silicon is a biocompatible and biodegradable [62; 63; 64]
material that has been investigated increasingly for its application in drug delivery [62; 65;
66; 67]. S1MP is manufactured by a combination of photolithography and electrochemical
etching in hydrofluoric acid. The etching offers tunable pore size and porosity rendering it
suitable for drug loading and conjugation of multiple targeting ligands [68] (Figure 3).
Photolithographic patterning of silicon wafers enables production of particles with
various geometries [69] (Figure 3), which are important for tuning their biodistribution and
tumor accumulation [70; 71]. The S1MP have been rationally designed for overcoming
various barriers en route to the tumor site. One of the major functions of S1MP is the
effective interaction with the microvasculature and docking to the endothelial cells or
fenestrations. Another task of the S1MP is to protect S2NP from degradation while in
circulation following intravenous administration.
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Figure 3: Tailoring geometry and porosity of S1MP. A1: Patterned SiN layer and trenches
etched into silicon. A2: Electrochemically etched S1MPs with release layer. A3: S1MP array
on wafer after removal of SiN. A4: Cross
Cross-section of hemispherical S1MP. B1: Photoresist
Photore
pattern on LTO capped porous silicon film with release layer. B2: Particle array on wafer
after RIE. B3: Discoidal S1MP array on wafer after LTO removal. B4: Released discoidal
S1MPs. C1: Silver nanopattern etched into silicon forming porous silicon nanowires. C2:
Nanowire barcode under white light. C3: SEM image of nanowire barcode. C4: 3-channel
3
confocal microscopy images of nanowire barcode with green Q
Q-dot
dot loaded in small pore
segment and red Q-dot
dot in bigger pore seg
segment. Reproduced with permission from [72].
Copyright 2014 American Chemical Society.
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Further, S1MP can be surface modified with various entities including, polyethylene
glycol (PEG) and other polymers [62], fluorescent probes [63], contrast agents, and
biologically active tumor-microenvironment targeting moieties including antibodies [73],
peptides [74], thioaptamers [75] and biomimetic membranes [76]. These studies demonstrate
that active targeting of S1MP to molecules overexpressed in the tumor microenvironment is
very efficient. For example, conjugation of E-Selectin targeted thioaptamer (ESTA) [75] or
arginine-glycine-aspartate (RGD) peptide [74] to the surface of S1MP enabled 20% and 10%
of injected dose (ID) accumulation in the tumor associated vasculature.
1.3.3

S2NP
Subsequent to accumulating in tumor associated vasculature, S1MP can release

second stage nanoparticles (S2NP) that are encapsulated in their pores. Liposomes[77],
quantum dots [59], SPION [78], polymeric micelles [79], gadolinium nanotubes [80] and
hollow gold nanospheres [81] are some examples of S2NP that have been successfully
loaded into S1MP. Figure 4 displays an overview of the different studies where S2NP were
loaded into S1MP.
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Figure 4: S2NP loading into S1MP. Various studies involving loading of different S2NP
into the pores of S1MP are presented; (I) quantum dots [59],, (II) liposomes [77], (III)
gadolinium nanotubes[80],, (IV) SPION [78],, (V) hollow gold nanospheres [81] and
polymeric
ic micelles containing paclitaxel [79].. All figures are reproduced with permission
from the respective journal.
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1.3.4

Challenges in designing molecularly targeted MSV
As described in earlier sections, loading of S2NP into S1MP and conjugation of

various targeting agents onto the surface of S1MP have been previously demonstrated
independently.
y. However, effective combination of the two processes poses several
challenges. Chemical conjugation of targeting ligands on the surface of S1MP reduces the
available surface area of pores available for the encapsulation of S2NP by as much as 75%
[75] (Figure 5). Additionally, chemical conjugation of peptides, antibodies or thioaptamers to
the surface of S1MP poses several technical challenges such as use of organic solvents for
thee conjugation, difficulty in the synthesis of the ligands, etc. all of which could adversely
affect the receptor-ligand
ligand binding capability [82] and may damage delicate S2NP [83].

Figure 5: Loading of S1MP with SPION following conjugation with ESTA. Iron content in
S1MP as measured by Inductively Coupled Plasma spectroscopy showing the decrease in the
amount of iron loaded into the S1MP following conjugation of thioaptamers on the surface of
S1MP. Reproduced with permission from [84].
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To overcome these challenges while combining both targeting S1MP and loading of
S2NP, we proposed a new technique that involves, first loading of the S1MP with S2NP
followed by decoration of the surface of S1MP with tumor targeted bacteriophage by
electrostatic interactions.
1.4

Targeting vascular zipcodes with bacteriophage

1.4.1

Filamentous bacteriophage and phage display
Bacteriophage are bacteria-specific virus which can be genetically modified to

express a tumor-homing peptide on one of its 5 coat proteins, without compromising its
infectivity [85]. This technique is called phage display [86]. The most commonly used phage
for this purpose is the filamentous fd-tet bacteriophage. These are nanowire-like virus,
measuring approximately 900nm in length and 7nm in width and having about 3900 copies
of the major coat protein (pVIII) and 5 copies each of the minor coat proteins (pIII, pVI, pVII
and pIX) (Figure 6). Bacteriophage expressing a tumor-targeting peptide on its coat proteins
offers various advantages over monoclonal antibodies and conventional polymers such as; (i)
non-toxicity, (ii) chemical and thermal stability, (iii) error-free and cost efficient mass
production and (iv) mono-dispersity [87]. Using this technology, several tissue-specific
surface receptor homing peptides have been identified. These peptides can be used to target
therapeutic or imaging agents to the tumor cells. One of the main features of phage display is
their ability to identify tissue-specific endothelial markers and the peptides that home to these
endothelial cells. Various endothelial-specific markers have been identified in prostate cancer
[88], in vitro HUVEC cultures [89], melanoma [90] and so on. Molecular signatures on
vascular endothelium can also be used to target and enhance the accumulation of circulating
nanovector at the tumor site [8]. Unlike tumor cells, these “vascular zip codes” seem to be
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more stable and do not give into chemotherapeutic resistance [91].. Further, endothelial cell
markers are the most accessible markers for any vascularly injected therapeutic agent, in
comparison to markers expressed on tumor cells or stromal cells. Thus, these markers should
be taken advantage of and used for homing ther
therapeutic
apeutic agents and nanoparticles to the tumor
site.

Figure 6: Bacteriophage structure and phage display
display. (A) TEM micrograph of
filamentous bacteriophage; (B) Schematic presentation of bacteriophage with the 5 coat
proteins.
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1.4.2

Identification of targeting ligand – CRKL binding peptide
Recently

Mintz

et

al.

identified

a

new

peptide

sequence,

YRCTLNSPFFWEDMTHECHA using phage display that showed marked tumor-homing in
prostate cancer xenografts [92]. This peptide had sequence similarity with the plexinsemaphorin integrin (PSI) domain of β1 integrin. Unexpectedly, the peptide bound to the
extracellular fraction of an intracellular adaptor protein, CRKL.
CRKL, a member of the Crk (CT10 Regulator of Kinase) protein family, was
originally identified as an intracellular adaptor protein in primary leukemic neutrophils from
patients with chronic myeloid leukemia (CML) [93]. The Crk group of proteins have been
implicated in a wide variety of intracellular signaling pathways involving

tumor cell

migration, invasion and survival [94]. Tissue expression of CRKL has been observed in
various solid tumors like gastric [95], lung [96; 97], prostate [92], hepatocellular carcinoma
[98] and breast cancers [99; 100] as a novel prognostic marker. A recent study by Fathers et
al. [99] established the role of Crk proteins in regulating aggressive basal breast cancers. In
these studies, over-expression of CRKL was associated with high-grade and proliferative
breast cancers with poor prognosis and decreased survival.
Proteins located in various intra and extracellular compartments can have multiple
functions based on their location [101]. When found intracellularly, CRKL has been
implicated in integrin mediated signaling by binding to various tyrosine phosphorylated
scaffold proteins such as C3G, paxillin and p130Cas, thus affecting adhesion and migration.
CRKL can also translocate to the nucleus and act as a nuclear adaptor protein for Stat5
regulating gene transcription through DNA binding [102]. While most of the studies on
CRKL have shown that it acts as an intracellular adaptor protein in cytoplasmic or nuclear
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compartments, a recent work by Mintz et al. demonstrated that the unphosphorylated form of
the protein is secreted out either by ABC transporters or when the tumor cell dies and can be
found in the extracellular compartment of tumor [92]. The proposed mechanism of action of
secreted CRKL involves binding to the PSI domain of β1 integrin to activate MAP kinase
pathway causing nuclear transcription and eventual cell migration and proliferation (Figure
7) [103]. Furthermore, a study with mutant cells lacking CRKL suggest an important role of
CRKL in β1 integrin mediated cell adhesion to extracellular matrix [104].
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Figure 7: A working model based on the switchblade integrin activation. A hypothetical
pathway used by extracellular (secreted and/or released) CRKL to activate the integrinmediated MAPK cascade to promote cell proliferation and migration is shown. Reproduced
with permission from [103].
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Based on these, we hypothesized that the secreted CRKL from tumor cells would also bind to
β1 integrins on endothelial cells of tumor associated vasculature and the CRKL targeting
peptide can be used to target nanovectors to the endothelial cell surface bound CRKL.
1.4.3

AuNP-bacteriophage networks
Peptide displaying bacteriophage themselves has been used in the past for multiple

biomedical applications such as biological sensing [105], stem cell differentiation [106] and
therapeutic delivery [82; 85; 107]. The bacteriophage can be also be used as building blocks
for bottom-up nanofabrication. Souza et al. demonstrated that these biocompatible and celltargeting bacteriophage can spontaneously organize into dense networks when combined
with gold nanoparticles (AuNP) [108], without the requirement for genetic modifications of
the pVIII major coat proteins or chemical conjugation between the bacteriophage and AuNP
(Figure 8). The AuNP-bacteriophage networks have unique optical properties that can
function as signal reporters for fluorescence and dark-field microscopy as well as near
infrared surface enhanced Raman scattering (NIR-SERS) spectroscopy [105]. The celltargeting ability of bacteriophage was enhanced due to the presence of AuNP in in vitro
melanoma cells. Au-bacteriophage networks were also detected in real-time by non-invasive
NIR-SERS in vivo [109].
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Figure 8: Schematic illustrating the electrostatic interaction of AuNP and bacteriophage.
Adapted with permission from from [105; 108].

1.5

Hypothesis
The hypothesis of this work is that porous silicon S1MP can spontaneously form

complexes with CRKL targeted Au
Au-bacteriophage networks, to form Bacteriophage
Associated Silicon Particles (BASP) while preserving the payload carrying potential and
enhancing the tumor specific
ecific accumulation of the S1MP (Figure 9).
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Figure 9: Schematic presentation of (A) Bacteriophage Associated Silicon particles
(BASP) that exhibit enhanced ability to marginate within blood vessels and adhere to tumor
associated endothelium. Once positioned at the tumor site, the BASP can release its
therapeutic or imaging payload to achi
achieve
eve the desired effect prior to complete biodegradation
of the carrier particle and (B) The assembly of BASP: Au
Au-bacteriophage
bacteriophage and non-spherical
non
S1MP. Reproduced from [83
83] with permission from The Royal Society of Chemistry.
Chemistry
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1.6

Significance
The aim of this study is to design multicomponent nanovectors capable of

overcoming sequential biobarriers using specific and independent components at each stage
and delivering substantial therapeutic agent to breast cancer tissue. The novelty of this
project lies in the use of simple, electrostatic interactions for targeting MSV to tumor
vasculature, while maintaining the superior payload carrying potential of the S1MP.

1.7

Objectives
The overall objective of this work was to develop a multifunctional drug delivery

vector targeted to breast cancer tissues with good payload carrying potential. To achieve this,
the following objectives were identified:
•

To identify a suitable vascular biomarker that can be used to target MSV in breast

cancer.
•

To design and characterize BASP

•

To evaluate payload carrying potential of BASP

•

To evaluate in vitro and in vivo targeting ability of BASP

•

To evaluate therapeutic efficiency of BASP
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CHAPTER 2: MATERIALS AND METHODS

2.1

Identification and evaluation of CRKL expression in in vitro, in vivo and clinical

samples
2.1.1

Cell culture
Human breast cancer cell lines MCF7, MDA-MB-231 and SUM159 were maintained

in Dulbecco’s Modified Eagles Medium (DMEM, Life TechnologiesTM, NY, USA)
supplemented with 10% fetal bovine serum (FBS, Life TechnologiesTM, NY, USA) and 1%
penicillin (100units/mL) and streptomycin (100µg/mL). Human breast epithelial cell line
(MCF10A) was maintained in DMEM/F12 media (Life TechnologiesTM, NY, USA)
supplemented with 5% horse serum (Life TechnologiesTM, NY, USA), 20ng/mL epidermal
growth factor (EGF, PeproTech, NJ, USA), 500µg/mL hydrocortisone (Sigma-Aldrich Co.,
MO, USA), 100ng/mL cholera toxin (Sigma-Aldrich Co., MO, USA), 10µg/mL insulin
(Sigma-Aldrich Co., MO, USA) and 1% penicillin and streptomycin.
Human umblical vein endothelial cells (HUVEC, Lonza Inc., USA) were maintained
in Endothelial Basal Medium -2 (EBM-2) supplemented with EGM-2 Bulletkit (Lonza Inc.
USA). Human microvascular endothelial cells (HMVEC, ATCC) were maintained in EBM-2
supplemented with EGM-MV bulletkit (Lonza).
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2.1.2

Tumor models
Orthotopic mouse models of breast carcinoma were developed by inoculating 5x104

EF43.fgf4 cells into the mammary fat pad of 5 – 7 week old Balb/C mice as previously
described [110]. The tumors were allowed to grow for 5 days and the mice were sacrificed to
harvest the tumor for immunohistochemical and immunofluorescence staining. Patient
derived tumor xenograft (2665A) and human cell line (MDA-MB-231) orthotopic xenograft
sections were kindly provided by Dr. Bhuvanesh Dave. Human cell line (SUM159) xenograft
sections and 4T1 cell line tumor sections were also collected for CRKL staining analysis. All
animal procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) of Houston Methodist Research Institute.
2.1.3

Patient samples
Progressive breast cancer tissue microarrays were purchased from the Cancer

Diagnosis Program (National Cancer Institute). A total of 94, formalin fixed and paraffin
embedded, tumor tissue blocks corresponding to samples from different stages of disease
progression classified using TNM (American Joint Committee on Cancer, VI edition) were
studied. Twenty three specimens of normal breast tissue surgically removed with the
cancerous tissue were used as controls. Patient related data including age, disease stage,
tumor size, nodal involvement, metastatic status, estrogen and progesterone receptor status
for the included specimens were provided. This study was approved by the Institutional
Review Board (IRB) at the National Cancer Institute. Informed consent was not required for
these samples.10x and 40x images were captured using a Nikon microscope and the intensity
of staining was measured using NIS elements software.
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2.1.4

Evaluation of surface bound CRKL by flow cytometry
Presence of CRKL on the surface of various cells was analyzed using CRKL antibody

by flow cytometry analysis. Cells grown to 80% confluency in 6 well plates were harvested
and incubated with CRKL antibody (Santa Cruz Biotechnology, TX, USA) for 45min
followed by incubation with APC-labeled secondary antibody (Santa Cruz Biotechnology,
TX, USA) for 1h. They were then washed and re-suspended in PBS for flow cytometric
analysis. Cells incubated with the secondary antibody alone were used as controls. Cells were
measured on a BD FACS Fortessa analyzer (BD Biosciences, CA, USA) using 561nm
excitation laser. Twenty thousand cells were counted for each sample. Analyses of flow
cytometric data focused only on live cells using electronic gate to identify the APC positive
events using BD FACSDivaTM software. All experiments were performed in triplicates.
2.1.5

Assessment of cellular localization of CRKL using immunofluorescence
The pattern of CRKL staining in cells was analyzed by immunofluorescence. Cells

were seeded in 8 chamber slides (BD Bioscences, CA, USA) with 80% confluency and
allowed to attach overnight. After fixation with 4% paraformaldehyde (PFA, Thermo
Scientific, IL, USA), they were ramdomly divided into two groups. In one group the cells
were permeabilized with 0.2% TritonTM X-100 (Sigma-Aldrich Co., MO, USA) for 5 min
and washed extensively. In the second group, the cells were not permeabilized, to specifically
analyze the membranal fraction of CRKL. Both categories were incubated with CRKL
antibody at 1:500 dilution for 1h at room temperature (RT), washed and incubated with
Dylight 594-conjugated goat anti-rabbit secondary antibody (Thermo Scientific, IL, USA) for
45min. After the cells were washed, they were fixed again with 4% PFA, mounted with
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DAPI containing Prolong gold (Life TechnologiesTM, NY, USA) and visualized under a
Nikon fluorescence microscope (Nikon Instruments Inc., NY, USA).
2.1.6

Evaluation of CRKL expression in tumor using immunohistochemistry and

immunofluorescence
Immunohistochemical staining was performed on paraffin-embedded tumor sections
to study CRKL expression pattern. After two washes the slides were blocked for 10min in
peroxidase followed by 2.5% horse serum (Life TechnologiesTM, NY, USA) for 10min;
reacted with anti-CRKL antibody (1:100) for 30min; washed three times; incubated for
15min with horse anti-rabbit IgG; reacted for 4min with diaminobenzidine; rinsed; counterstained with hematoxylin; mounted; and imaged. The intensity of staining was determined by
image analysis using Nikon’s imaging software – NIS elements.
Cryosections were fixed in cold acetone for 5min, air dried and subsequently blocked
with 5% goat and horse serum in PBS for 30min at RT. Sections were then incubated with
primary antibodies (CRKL antibody and anti-CD31 antibody) for 1h at RT or overnight at
4°C, washed and incubated for 1h with APC conjugated anti-rabbit antibody and FITC
conjugated anti-mouse IgG. Tissue sections were washed, mounted and imaged using Nikon
A1 confocal microscope or Nikon fluorescence microscope.
2.2

Nanovector design and fabrication

2.2.1

S1MP fabrication
“S1MP were fabricated by integration of photolithography and electrochemical

etching of p-type silicon wafers in the Microelectronics Research Centre at The University of
Texas at Austin, as previously described [59; 71]. Briefly, the dimensions of S1MP were
defined by photolithography while the porous structure was formed by electrochemical
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etching of silicon in a mixture of hydrofluoric acid (HF) and ethanol. Particles with different
geometries and porosities were evaluated in this study including quasi-hemispherical and
discoidal particles with mean pore sizes of 20–30nm or 50–60nm. Photolithography followed
by electrochemical etching was used to make quasi-hemispherical S1MP [69]. For discoidal
S1MP, electrochemical etching was performed before photolithography [9]. The current
density was varied to obtain different pore sizes. Unmodified S1MP were retained on the
substrate for washing steps, and then released by sonication in isopropyl alcohol (IPA). The
particles were dried, and oxidized in a piranha solution (3:1 solution of sulfuric acid and 30%
hydrogen peroxide) at 100-110ºC for 2h to yield S1MP with negative surface charge
[S1MP(-)]. To produce S1MP with positive zeta potential [S1MP(+)], S1MP(-) were reacted
with 2% 3-aminopropyltriethoxysilane (APTES, Sigma-Aldrich Co. LLC, USA) for 2h at
35°C. The modified particles were re-suspended and stored in IPA. Immediately before use,
the particles were washed thrice and re-suspended in distilled water. The concentration
(counts/mL) of S1MP was obtained using a MultisizerTM 4 Coulter Counter (Beckman
Coulter, USA). The zeta potential was measured with ZetaPALS (Brookhaven Instruments
Corporation, USA).” [83]
2.2.2

AuNP synthesis
“Gold nanoparticles (AuNP) were prepared using the common Turkevich method

[111] with a ratio of 1:0.8 of Gold(III) chloride and trisodium citrate (Sigma-Aldrich Co.
LLC, USA) to yield ~45nm particles. The resulting AuNP colloid solution was concentrated
by sequential centrifugation steps at 2600xg in Sorval Legend X1R Centrifuge (USA) for 10,
15 and 20min at 4°C to achieve an absorbance of approximately 5A.U. at 530nm. The
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hydrodynamic radius and the zeta potential measurements of AuNP were performed using
ZetaPALS.” [83]
2.2.3

Bacteriophage isolation
“Bacteriophage particles were obtained as previously described [112]. Briefly,

filamentous bacteriophage, both native (fd-tet) and YRCTLNSPFFWEDMTHECHA
peptide-displaying (CRKL targeted), were grown by infection of K91 Escherichia coli
(E.coli) bacteria overnight at 37°C and were subsequently isolated by PEG precipitation [82;
113]. The final pellet was resuspended in phosphate-buffered saline (PBS). Endotoxin free
bacteriophage were obtained by phase separation using TritonX-114[114]. Bacteriophage
titers or transducing units (TU) were determined by infecting E.coli and screening for
tetracycline resistant colonies. Fluorescently labeled bacteriophage was used for
identification by confocal microscopy when needed. The bacteriophage particles were
conjugated with a 1000 fold excess of Dylight 594 (Thermo Fisher Scientific Inc., USA) for
1.5h and precipitated using PEG.” [83]
2.3

Assembly of Bacteriophage Associated Silicon Particles (BASP)
“AuNP-bacteriophage networks were obtained based on the previously published

method [105] with a bacteriophage input of 2.5x107 TU/µL. Two-fold serial dilutions of
bacteriophage were done in distilled water and equal volumes of AuNP were added to each
dilution and left undisturbed overnight at RT. The formation of AuNP-bacteriophage
networks was noted by a change in colour of the solution from red to purple [105]. AuNPbacteriophage networks were concentrated and incubated with S1MP for 1h with intermittent
vortexing to form BASP.” [83]
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2.4

Characterization of BASP

2.4.1

Visualization of BASP formation
The morphology of the BASP was examined using various microscopic techniques.

2.4.1.1 Confocal microscopy
“For identification during confocal microscopy studies, S1MP(+) were loaded with
fluorescein isothiocyanate conjugated bovine serum albumin (BSA-FITC, Sigma-Aldrich Co.
LLC, USA). For this purpose 107 S1MP(+) were desiccated to remove any residual IPA. To
the dry S1MP(+) 200µL of 5mg/mL aqueous solution of BSA-FITC was added and the
system was incubated for 2h at 4ºC under rotation. The loaded particles were washed thrice
in distilled water and incubated with Dylight 594 conjugated bacteriophage to form BASP
and were visualized under a Leica DM6000 upright confocal microscope (Leica
Microsystems, Germany) equipped with a 63X oil immersion objective.” [83]
2.4.1.2 Transmission Electron Microscopy
“For transmission electron microscopy (TEM), samples were placed on 100 mesh
coated copper grids treated with poly-l-lysine for 1h. Excess samples were blotted with filter
paper and the BASP were stained with filtered aqueous 1% ammonium molybdate and 0.02%
BSA, pH 7.0 for 1min. The samples were blotted, allowed to dry and imaged using the AMT
Imaging System (Advanced Microscopy Techniques Corp., Danvers, MA) JEM 1010 TEM
(JEOL, USA, Inc., Peabody, MA) at 80kV fitted with an AMT Advantage digital CCD
camera system.” [83]
2.4.1.3 Scanning Electron Microscopy
“BASP solutions were dried on cleaned SEM stubs overnight in a desiccator and
sputter-coated with a 5nm layer of gold, using a Plasma Sciences CrC-150 Sputtering System
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(Torr International, Inc.). Scanning electron microscopy (SEM) images were acquired under
high vacuum, at 20kV, spot size 3 – 5, using an FEI Quanta 400 FEG ESEM (FEITM, USA)
equipped with an ETD (SE) detector.” [83]
2.4.2

Effect of porosity and zeta potential of S1MP on BASP formation
“To study the effect of surface charge and porosity of S1MP in the formation of

BASP, we incubated the systems with various geometries, porosities and surface charges of
S1MP. The geometries of S1MP varied from quasi-hemispherical to discoidal to cylindrical
with size ranges between 0.4µm to 3µm. The pore sizes of S1MP used were either 20-30nm
(huge pore, HP) or 40-60nm (giant pore, GP). The surface charge of the S1MP used was
modified by oxidation to yield a negative zeta potential or by silanization to yield a positive
charge as described earlier.” [83]
2.4.3

Evaluation of contact angle
“The hydrophilicity of the systems was determined by measuring the contact angles

made by the sample solution resting on a flat horizontal solid surface using captive bubble
contact angle goniometry.” [83]
2.4.4

Spectral characteristics of BASP
“Light spectroscopy was used to study the absorption characteristics of BASP during

their formation. Shifts in the absorbance spectra of AuNP towards the NIR wavelengths were
evaluated using SpectraMax M2 spectrophotometer (Molecular Devices, USA) or Biotek
Synergy H4 hybrid multimode microplate reader (BioTek® Instruments, Inc., USA).
For SERS, BASP were excited by a fiber-optic probe delivering 785nm laser light for
10s.

The resulting Raman scattering data (average of 3 results) were gathered on a

PerkinElmer Raman Station 400F (PerkinElmer Inc., USA) after background subtraction
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with water. The spectra were analyzed with Spectrum software (PerkinElmer Inc., USA).”
[83]
2.4.5

Thermal effects of BASP

“The enhanced absorbance in the NIR region prompted the use of NIR laser to test the
heating potential of BASP. 200µL of the sample solution was exposed to Delta 810nm diode
laser (AngioDynamics UK Ltd.) with an output of 10J/cm2 for 250msec at an interval of
100msec for a total of 10min using a 2mm fixed focus spot hand-piece. The resulting change
in temperature was measured using an OxyLiteTM probe (Oxford optotronix Ltd., USA).”
[83]
2.5

In vitro degradation of BASP
“BASP or S1MP (5x107, 1.6µm quasi-hemispherical) were suspended in 1mL of

100% FBS and incubated at 37°C with constant mixing in a rotary shaker for predetermined
times. Aliquots (100µL) were taken at specified time intervals namely 0, 0.5, 1, 4, 8, 24 and
48h. For quantitative analysis of elemental silicon in the degradation medium, 90µL of the
aliquots were filtered through a microcentrifuge filter to separate the non-degraded S1MP
from the degradation products, diluted with water and analyzed using Varian 720-ES
Inductively Coupled Plasma – Optical Emission Spectrometer (ICP-OES, Varian Inc., USA)
set at 1kW, with plasma flow set to 15L/min, auxiliary flow of 1.5L/min and a nebulizer flow
of 0.75L/min. Silicon contents in the degradation medium was detected at 250.69nm,
251.43nm, 251.61nm and 288.158nm using 1ppm of Yttrium as an internal control. The
remaining 10µL were washed thrice with deionized water to remove salts and proteins and
processed for SEM analysis as described above.” [83]
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2.6

Loading of S2NP
“S1MP (1.5x108, 1x0.4µm discoidal, 20-30nm pore size) and E-Selectin thioaptamer

conjugated S1MP (ESTA-S1MP) were dried in a desiccator. For ESTA-S1MP, the S1MP
were conjugated with a 107 fold excess of thioaptamers using PolyLink Protein Coupling kit
for 1h as described earlier [75]. Amine modified SPION (15nm) suspended in PEG was
centrifuged at 2000rpm for 5min at RT to remove aggregated particles. The supernatant was
used as the stock for loading experiments. SPION solution (25µL) was added to S1MP and
incubated for 30min with intermittent sonication. The SPION loaded S1MP were washed
twice with water and then incubated with 15µL AuNP-bacteriophage networks for 1h to
allow the assembly of BASP. The BASP were washed an additional time to remove any
unbound SPION. NMR relaxation profiles of the SPION loaded particles were measured
using a Bruker Minispec mq-60 bench-top relaxometer (Bruker Optics Inc., USA) operating
at 60MHz and 37°C. The solutions were then digested for evaluation of elemental iron by
heating them with nitric acid at 120°C thrice until the acid evaporated. The sediments were
then resuspended in water. The iron content was detected at 238.204nm and 259.940nm
using ICP-OES as previously described.
S1MP (1.5x108, 1x0.4µm discoidal, 20-30nm pore size) were loaded with 20µL of
2µM carboxylated quantum dots (QD) in a process similar to the SPION loading. Following
BASP formation, the particles were visualized under fluorescence microscope to see if the
QD are confined to the S1MP in the BASP or are released and entrapped in the AuNPbacteriophage networks during the BASP formation. The samples were also digested using
nitric acid and analysed for Cadmium content using ICP-OES.” [83]
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S1MP were loaded with Abraxane also using the wet incipient method. Abraxane was
reconstituted at 1.5mg/20µL of distilled water and added to 1x109 S1MP. After 1h of rotation
at RT, the S1MP were either reconstituted in a total of 100µL water or AuNP-bacteriophage
networks to form BASP.
2.7

In vitro studies

2.7.1

Evaluation of cellular association of BASP
To study the in vitro behavior of BASP, endothelial cell lines (HUVEC and HMVEC)

and breast cancer cell line (MCF7) with the maximum amount of surface CRKL were
incubated with BASP and observed. HUVEC and HMVEC were seeded at 200,000 cells/well
in a 12 well plate (BD Falcon) and allowed to grow overnight at 37ºC. Cells were blocked
with 30% FBS for 1h at 37ºC and were incubated with BSA-FITC (Sigma Aldrich) loaded
S1MP, non-targeted BSA-FITC loaded fd-tet BASP or CRKL targeted BSA-FITC loaded
BASP for upto 1h. The cells were subsequently washed, fixed with 4% PFA and resuspended
in PBS for analysis by flow cytometry.
MCF7 cells seeded at 70% confluency on 8 chamber microscope slides (BD Falcon)
and allowed to grow overnight at 37°C. Cells were blocked with 30% FBS for 1h at 37°C
and were incubated with BSA-FITC (Sigma Aldrich) loaded S1MP, non-targeted BSA-FITC
loaded fd-tet BASP or CRKL targeted BSA-FITC loaded BASP for 6h. The cells were
subsequently washed and fixed with 4% PFA, permeabilized with 0.2% Triton X-100 and
blocked with 1% BSA (SigmaAldrich) for 1h. The phage were stained with rabbit anti-phage
primary antibody (Sigma Aldrich) followed by Dylight-594 tagged goat anti-rabbit secondary
antibody. The cells were stained with nuclear stain, Draq 5 (Biostatus Ltd.), fixed and imaged
using a Leica Confocal microscope.
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MCF7 cells were plated in 24 well plates containing 5 x 5mm Silicon Chip Specimen
Supports (Ted Pella, Inc., Redding, CA) at 70% confluency. Cells were incubated with
S1MP, fd-tet BASP or CRKL targeted BASP (5 particles/cell) at 37ºC for 6h. Samples were
washed with PBS and fixed in 2.5% glutaraldehyde (Sigma-Aldrich) for 30min and
processed for SEM analysis as described previously [115]. Briefly, the cells were dehydrated
in a step-wise manner in increasing concentrations of ethanol (30%, 50%, 70%, 90%, 95%
and 100%) for 10min each. The cells were then incubated in 50% t-Butanol for 10min
followed by incubation in 100% t-Butanol for 5min and overnight incubation in a dessicator.
Specimens were then mounted onto SEM stubs (Ted Pella, Inc.) with conductive adhesive
tape, sputter coated with 5nm layer of gold and imaged under high vacuum, at 20-30 kV, spot
size 3.0-5.0, using a FEI Quanta 400 FEG ESEM equipped with an ETD (SE) detector.
MCF7 cells were grown to 70% confluency in a 24 well plate and incubated with
S1MP, fd-tet BASP or CRKL targeted BASP (5 particles/cell) at 37ºC for 6h. Cells were
washed and fixed in a solution of 2% PFA and 3% glutaraldehyde in PBS, pH 7.4 for 1h at
RT. Samples were processed for TEM as described previously [115]. Briefly, the samples
were washed with 0.1% cacodylate buffered tannic acid, fixed with 1% osmium tetroxide for
30min and stained with 1% uranyl acetate. The cells were then dehydrated in increasing
concentrations of ethanol as described before, infiltrated, embedded in Poly-bed 812 medium
and polymerized for 2 days at 60ºC. Ultra-thin sections were cut and stained with uranyl
acetate and lead citrate. The samples were imaged in a JEM 1010 TEM microscope as
described above.
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2.7.2

Evaluation of interaction with endothelial cells under shear stress
HUVEC or HMVEC cells were seeded at 1.5x107 cells/mL density on fibronectin

coated Bioflux microfluidic 48 well plates (0-20 dynes/cm2) and allowed to grow overnight.
To activate endothelial cells, cells were seeded and allowed to attach for 1h. They were then
incubated with conditioned media from EF43.fgf4 cells overnight. Cells were then treated at
37ºC with one of the following: Alexafluor 555 conjugated S1MP, fd-tet BASP or CRKL
targeted BASP under constant linear flow at either 10s-1 or 100s-1 shear rates at a
concentration of 107 particles/mL. Briefly, APTES modified particles (1x109) were incubated
with 0.5mg/mL solution of Alexa fluor 555 (Life TechnologiesTM, NY, USA) for 1h at RT.
The particles were then washed to remove unbound dye and again APTES modified before
BASP formation. The flow of the particles over the cells was recorded by taking timelapse
images in the TRITC channel at 12 frames per second for 1h using a 20X objective on an
inverted Nikon microscope. The particles were removed and replaced with fresh media and
the cells were monitored for an additional 16h with images being taken every 1h. The
velocity of particles rolling on the cell surface and the number of particles attached were
analyzed using NIS elements software equipped with 2D tracking component.
2.8

In vivo studies

2.8.1

Evaluation of targeting efficiency of CRKL targeted BASP
Breast cancer allografts were grown in immunocompetent Balb/c mice by injecting

5x104 EF43.fgf4 cells orthotopically in the mammary fat pad. After 10 -14 days, the mice
were randomly divided into 4 groups and administered intravenously with one of the
following: PBS, S1MP, fd-tet BASP or CRKL targeted BASP formed with 5x108 S1MP
(1.6µm quasi-hemispherical). The bacteriophage used in these experiments were either
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labeled with Dylight 594 or unlabeled. Four hours following the administration of the
systems, the animals were sacrificed and the liver and tumor were collected for histological
analysis (conventional and hyperspectral microscopy). Paraffin embedded tissue sections
were stained for bacteriophage by incubating with anti-bacteriophage antibody (Sigma
Aldrich Co. LLC., USA) at 1:750 dilution for 30min. Frozen tissue sections from mice
injected with Dylight 594 labeled bacteriophage containing BASP were counterstained for
nucleus with Draq5 (Biostatus Limited, UK). Non-stained paraffin embedded tissue sections
were fixed with 4% PFA, mounted with Prolong gold mounting media (Invitrogen, USA) and
imaged using a darkfield condenser from CytoViva attached to an Olympus BX41
microscope and DAGE camera/software (CytoViva, Auburn, AL 36830) hyper-spectral
imaging system that can identify material at resolutions of less than 100nm based on the
material’s unique spectral signatures.
2.8.2

Evaluation of therapeutic efficacy of CRKL targeted BASP
Abraxane was purchased from MD Anderson Cancer Center (Houston, TX)

pharmacy and diluted in water before use. To assess the therapeutic activity of S1MP or
CRKL targeted BASP loaded with Abraxane, Balb/C mice bearing orthotopic EF43.fgf4
tumors on either side of their body were randomly divided into 4 groups (5 mice/group) and
treated with: (i) PBS, (ii) Abraxane (Abx) (75mg/kg), (iii) S1MP-Abx (75mg/kg) or (iv)
CRKL targeted BASP-Abx (75mg/kg). The mice were treated every third day and the tumor
size was monitored every other day using calipers until the 11th day
2.8.3

Intravital microscopy for studying particle flow characteristics
Orthotopic breast tumor bearing mice were randomly selected for intravital

microscopy studies on days 5 and 10. The anaesthetized mice were surgically opened to
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expose the tumor mass, positioned on a heated stage and injected with 5x108/100µL particles
of either Alexa Fluor 555 labeled S1MP or fd-tet BASP or CRKL targeted BASP.
Immediately following injection, three channel images were acquired as a time lapse video at
30 frames per second using a 40x0.6 NA objective. Animals were imaged for 1h and then
sacrificed as described above, to collect organs for histological analysis.
2.9

Evaluation of CRKL as a soluble biomarker

2.9.1

Collection of conditioned media (CM) for evaluation of secreted CRKL
Conditioned media (CM) were collected from SUM159 and MCF10A cell lines. The

cells were seeded at 50% confluency overnight, washed with PBS and incubated with serum
free media for 24h. The media was then collected, centrifuged at 5000rpm for 10min and the
supernatant was stored at -80°C until analysis by ELISA.
2.9.2

Evaluation of secreted serum fraction of CRKL in in vivo models
Blood from nude mice grafted with patient derived breast tumors (2665A) were

collected for enzyme linked immunosorbant assay (ELISA). All animal procedures were
approved by the Institutional Animal Care and Use Committee (IACUC) of Houston
Methodist Research Institute.
2.9.3

Collection of patient serum samples
Twenty nine breast cancer patients’ sera and 9 healthy donor serum samples were

purchased from Promeddx, LLC (Massachusetts) and tested for soluble CRKL fraction by
ELISA. As in the tissue microarrays, the serum samples were from patients with different
stages of disease progression classified using TNM staging. Twenty five out of the twenty
nine patients were undergoing treatment. This study was approved by the IRB at Promeddx
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LLC. Informed consent was obtained or implied by return of questionnaires at the
physician’s site.
2.9.4

Evaluation of soluble fraction of CRKL by Enzyme Linked Immunosorbant

Assay
The levels of secreted CRKL in cell culture supernatants, serum samples from mice
bearing 2665A breast tumors and breast cancer patients sera were analyzed using
commercially available ELISA kits (Cloud-Clone Corp., TX, USA) according to
manufacturer’s instructions. The CRKL concentrations are expressed as pg/mL of blood
plasma. Detection limit was 53pg/mL.
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CHAPTER 3: RESULTS

3.1 CRKL as a cell surface biomarker
3.1.1

Localization on cell surface
A previous study has shown that CRKL, originally an intracellular protein is secreted

by tumor cells into the tumor microenvironment [92]. We speculated that “the secreted
CRKL from tumor cell lines would bind to the surface of cells through interaction with β1
integrin. To evaluate the membrane bound fraction of secreted CRKL, non-permeabilized
breast cancer cells were analyzed by flow cytometry. The percentage of cells with surfacebound CRKL varied among different cell lines. Cancer cell lines (MCF7, MDA-MB-231 and
SUM 159) showed 3 – 5 fold higher percentage of staining than mammary epithelial cell line
(MCF10A). For instance 93.7% of MCF7 cells have surface bound CRKL when compared to
55.6% on SUM159 cells and only 17% on MCF10A cells (Figure 10A).” Murine breast
cancer cell lines EF43.fgf4 and 4T1 also showed very high staining for CRKL – upto 80%.
We also looked at the surface localization of CRKL in endothelial cells. The surface
fraction of CRKL in endothelial cells can serve as an indicator of the fraction released from
cancer cells. Moreover, since β1 integrin is overexpressed on angiogenic vasculature, we
hypothesized that higher fractions of CRKL will be bound to the surface of tumor associated
endothelial cells. The levels of surface bound CRKL were 82.2±4.7%, 25.9±12.7% and
13.7±1.1% for SVEC, HUVEC and HMVEC respectively (Figure 10B). Addition of cancer
cell conditioned media (EF43.fgf4 – CM) to HMVEC increased the surface localization of
CRKL on HMVEC by about 2 fold (Figure 10C).
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Immunofluorescence staining of the various cell lines confirmed the presence of
CRKL on the cell surface. The lack of co-localization of nuclear (DAPI) and CRKL staining
in non-permeabilized cells confirmed that the observed staining is the surface-bound fraction
of CRKL. On the other hand, permeabilization of the cells led to the staining of the
cytoplasm and the nuclear region showing that, as expected, a large fraction of the protein is
present in intracellular compartments (Figure 10D).

43

Figure 10: Surface localization of CRKL in breast cancer cells in vitro. Flow cytometry
on non-permeabilized cells showing surface fraction of CRKL in (A) breast cancer and
epithelial cell lines; (B) endothelial cell lines and (C) HMVEC incubated with cancer
conditioned media. (D) Immunofluorescence images of human breast cancer and endothelial
cells showing the difference in the staining pattern of CRKL (red) in permeabilized (bottom
row) and non-permeabilized (top row) cells. The cells are counterstained with wheat germ
agglutinin 488 for the cell membrane (green) and DAPI for the nucleus (blue). (Scale bar =
20µm)
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3.1.2

Expression in in vivo and clinical tumor biopsies
Next, we “evaluated the patterns of CRKL expression in in vivo breast tumor models

originated from a human clinical specimen (2665A) and human breast tumor cell lines MDAMB-231 and SUM159. MDA-MB-231 xenografts exhibited cytoplasmic/membranal staining
for CRKL, while SUM159 and patient derived xenograft 2665A showed stronger nuclear
staining with mild cytoplasmic and extracellular staining.” Murine breast tumor models from
EF43.fgf4 and 4T1 exhibited mainly extracellular CRKL staining (Figure 11A).
To evaluate the CRKL expression in human breast cancer specimens, we
immunostained paraffin embedded cancer progression tissue microarrays with a total of 94
tumor cores (Figure 11B). It was noted that normal breast tissue stained positive for CRKL
only in the ductal epithelium, therefore, during the pathological examination of the tumor
tissue, the regions of ductal epithelium were excluded. More than 90% of the patients were
Caucasians. Twenty seven patients were estrogen receptor (ER) negative and 46 were
progesterone receptor (PR) negative. The average tumor size of the entire set of patients was
2.6 cm (range from 1 to 6.5 cm).
Similar to in vivo studies, the staining pattern in tumor tissue varied from nuclear to
cytoplasmic to microenvironmental. Overall, about 85% of the breast cancer clinical samples
stained positive for CRKL. The average intensity of CRKL (A.U./pixel), as measured by
image analysis, was about 12 fold higher in breast tumor biopsies than in the uninvolved
breast tissue (46.8±22.1 vs 3.9±1.9 A.U./pixel, respectively, Figure 11C). Table 3
summarizes the correlation of CRKL staining and the clinicopathological factors.
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Figure 11: CRKL expression in in vivo samples and clinical tumor biopsies.
biopsies (A)
Immunohistochemistry for CRKL in (A) primary breast cancer xenografts (Scale bar =
50µm); (B)) Immunohistochemistry of human breast cancer tissue microarray showing (i)
strong and (ii) weak staining of invasive ductal carcinoma tissues, (iii) normal breast tissue
showing positive staining mainly in the ductal ep
epithelium.
ithelium. (Scale bar = 100µm) (C)
(C
Quantitation of intensity of staining through image analysis in tumor cores (early and
advanced disease)
sease) and normal breast tissues.
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To confirm our findings regarding surface fraction of CRKL on endothelial cells from
in vitro studies, we tested co
co-localization of CRKL and endothelial marker (CD31 for breast
cancer allografts and CD34 for human tissue microarray) staining in histological
histol
tumor
sections. A stronger CRKL staining on tumor associated endothelial cells as compared to the
overall tumor mass staining was observed in both the animal model (Figure 12A) as well as
the tissue microarray (Figure 112B,C,D).

Figure

12:

Co-localization
alization

of

CRKL

and

tumor

associated

vasculature.

Immunofluorescence
ofluorescence staining of CRKL and (A) CD31 in EF43.
EF43.fgf4 breast allograft model;
(B,C,D) CD34 in human breast cancer tissue microarray biopsies, showing co-localization
co
of
CRKL and vascular endothelial cells in the tumor.
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Parameters

Staining intensity of CRKL in breast cancer tissue
microarray
Negative
Positive
Number
%
Number
%
P

Age
10
19.6
41
80.4
<60 years
9
20.9
34
79.1
>60 years
T stage
7
16.2
36
83.8
T1
8
20
32
80
T2
1
33.3
2
66.7
T3
3
37.5
5
62.5
T4
Nodal involvement
3
9
30
91
Negative
11
24.4
34
75.6
Positive
Metastatic involvement
10
16.4
51
83.6
Negative
9
27.3
24
72.7
Positive
Tumor size
7
15.9
37
84.1
< 2 cm
12
24
38
76
> 2 cm
Estrogen receptor
4
14.8
23
85.2
Negative
15
22.4
52
77.6
Positive
Progesteron receptor
7
15.2
39
84.8
Negative
12
25
36
75
Positive
Table 3: Relationship between CRKL expression and clinicalpathological parameters

0.86

0.001

0.007

0.08

0.22

0.27

0.11

Based on the above observations, we decided to see if the extracellular fraction of
CRKL could serve as a target for targeted drug delivery of nanovectors.
3.2 Physical characterization of BASP
3.2.1

Assembly of BASP
“BASP are comprised of three components: S1MP, AuNP and bacteriophage. The

addition of AuNP to bacteriophage causes instantaneous agglomeration of AuNP noted by
the color change from red to purple [105] and the condensation of the system into fibrous
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structures as seen in Figure 13A, similar to what was previously reported by Souza et
al.[105] Addition of these condensed AuNP-bacteriophage networks to S1MP resulted in
spontaneous association between the components forming BASP. To verify the formation of
BASP we used confocal microscopy and TEM. Fluorescently labeled bacteriophage used in
the assembly of BASP clearly showed co-localization of the bacteriophage (red) and the
BSA-FITC loaded S1MP (green) (Figure 13B). Further, TEM micrographs showed the close
association of fibrous bacteriophage (white lines) and AuNP (black dots) with S1MP (a large
porous structure) (Figure 13C).” [83]
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Figure 13: Visualization
alization of the BASP formation
formation. (A) Macroscopic view on network/gel
formation corresponding to the association of AuNP
AuNP-bacteriophage
bacteriophage networks with S1MP to
form BASP at serial dilutions of the bacteriophage starting from the concentration of
3.87x105 TU/µL ; (B) Confocal microscopic imag
imagee of BASP with BSA-FITC
BSA
loaded
S1MP(+) (Green) and Dylight594 labeled phage (Red) showing the specific co-localization
co
of the two; (C) TEM image of BASP showing the S1MP surrounded by AuNP(arrow heads)
and bacteriophage(arrows). Reproduced from [83] with permission from The Royal Society
of Chemistry.
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“Optimization
Optimization processes in tthe assembly of BASP involved incubation of various
concentrations of the components in a systematic manner. It was seen that the concentration
of AuNP (OD 1 to 7) did not affect the formation of BASP, while excessively high
concentrations of silica beads (>106/µL) prevented their formation (Figure 14A).
14
Also, it was
found that formation of BASP was most efficient when assembled in a two-step
two
process
involving: (1) the formation of dense AuNP
AuNP-bacteriophage networks; followed by the (2)
coating of S1MP by these networks (Figure 14
14B).” [83]
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Figure 14: Effect of concentration and order of incubation on the formation of BASP
(A) Photographs showing the assembly of BASP with different concentrations of the
components. The red color is due to the presence of AuNP. Note the condensation and the
color change in the solution (highlighted in the blue box) at bacteriophage concentrations of
3.5x106, 1.75x106 and 8x105 TU/µL in A as opposed to the absence of such changes in B. (B)
SEM micrographs of BASP with silica beads. Left: BASP formation when bacteriophage
was added to a mixture of silica beads and AuNP. Right: BASP formation when AuNPbacteriophage networks were added to silica beads. Note the significant increase in the
number of AuNP (white dots) and the presence of fibrous coating on the silica beads
(bacteriophage) in B. Adapted and reproduced from [83] with permission from The Royal
Society of Chemistry.

3.2.2

Effect of porosity and zeta potential of S1MP on BASP formation
“We compared non-porous spherical silica beads to quasi-hemispherical and discoidal

mesoporous silicon particles with different pore sizes in their ability to form BASP. Although
the shape of S1MP used did not have much effect on the self-assembly of BASP, the
association of AuNP to porous particles was evidently better than their association to nonporous silica beads (Figure 15).” [83]
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Figure 15: BASP design- effec
effect of S1MP geometry and porosity. (A) SEM images of
BASP formed in the presence of S1MP(
S1MP(-)) with different geometries and porosities. The
images show the association of S1MP with AuNP. The systems are as follows: (a) 1.6µm in
diameter quasi-hemispherical
hemispherical HP (b) 1µm in diameter and 0.4µm in height discoidal GP (c)
3.2µm in diameter quasi-hemispherical
hemispherical HP (d) 1µm in diameter and 0.4µm in height
discoidal HP (e) 0.6µm in diameter and 0.4µm in height discoidal HP (f) 1µm in diameter
spherical solid silica beads. GP – pore size 40 – 60nm, HP – pore size 20 – 30nm, Scale bar 300µm. Reproduced from [83
83] with permission from The Royal Society of Chemistry.
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“The surface potential of drug delivery vehicles is another important feature to be
considered in their design. The effect of zeta potential of S1MP on the formation of BASP
was evaluated by comparing BASP containing 1.6µm quasi-hemispherical S1MP(+) and
S1MP(-). The initial and final zeta potential values of the systems are presented in Figure 16
For S1MP(+) and S1MP(-), the initial zeta potential values were 8.9 ± 1.9mV and -25.7 ±
1.3mV respectively. The AuNP-bacteriophage networks have a net negative charge. After the
formation of BASP, both systems yielded similar negative zeta potentials meaning that the
significant shift in zeta potential values occurred only during the formation of BASP
containing S1MP(+). Morphological examination of the resulting systems by SEM confirmed
this behavior. In agreement with the zeta potential data, SEM micrographs show more
efficient association of AuNP-bacteriophage networks with S1MP(+) particles (Figure 16
inset).” [83]
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Figure 16: Effect of surface zeta pote
potential
ntial of S1MP on BASP formation. Zeta potential
of BASP and their components (inset) SEM image of BASP with S1MP(-)
S1MP( and S1MP(+)
showing better adhesion of AuNP
AuNP-bacteriophage networks to the S1MP(+)
1MP(+) in comparison to
S1MP(-). Reproduced from [[83] with
th permission from The Royal Society of Chemistry.
Chemistry
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3.2.3

Evaluation of BASP contact angle
“Hydrophilicity
drophilicity measurements on BASP showed that both types of BASP, containing

either S1MP(+) or S1MP(-)) (Figure 17)) are more hydrophilic than AuNP solution alone,
which can be important for avoiding non
non-specific
specific uptake by cells of the reticuloendothelial
system, as shown for nanovectors modified on their surface with hydrophilic polymers, such
as PEG [116].” [83]

Figure 17: Contact angle measurements of BASP showing an increase in hydrophilicity in
comparison to AuNP or AuNP
AuNP-bacteriophage. Reproduced from [83] with permission from
The Royal Society of Chemistry.
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3.2.4

Spectral characteristics of BASP
“As mentioned
ned above, the formation of AuNP-bacteriophage
bacteriophage networks can be

monitored in real-time
time using UV
UV-Vis
Vis spectroscopy. Instantaneous interaction between the
components of AuNP-bacteriophage
bacteriophage networks in successive serial dilutions of the
bacteriophage solution (5x10
x106 TU/µL to 5x105 TU/µL)) is indicated by the broadening and
reduction of UV-Vis
Vis absorbance at 530nm and simultaneous increase in the absorbance at
NIR wavelengths between 650nm and 800nm.
800nm.[105] This observed 3-4
4 fold increase in NIR
absorbance occurs within 20sec of the addition of AuNP to bacteriophage. The AuNPbacteriophage with enhanced NIR absorbance are then pooled together and incubated with
S1MP to form BASP. The increase of the absorban
absorbance
ce in the NIR region was maintained
following the formation of BASP (Figure 18).” [83]

Figure 18: UV-Vis
Vis spectra of BASP show 2-3
3 fold increase in the NIR absorbance of BASP
in comparison with the same concentration of AuNP. Reproduced from [83]] with permission
from The Royal Society of Chemistry.
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“The
The high absorbance in the NIR region enables the use of spectral properties of the
systems for diagnostic and therapeutic purposes. As an example, use of SERS as a diagnostic
tool was investigated and the NIR
NIR-SERS spectra of BASP were recorded. As shown above,
AuNP is closely associated with bacteriophage and S1MP in BASP. The close association of
AuNP to bacteriophage
eriophage facilitated an increase (~2000 fold) in the signature Raman peaks of
the bacteriophage major coat proteins (such as phenylalanine and alanine).
alanine) The data
presented in Figure 19 illustrates the enhancement of unique peaks, namely wavenumbers
1022cm-1, 1001cm-1 and 995cm-1[117; 118; 119], in the NIR-SERS
SERS spectra of bacteriophage
bacterio
associated with the BASP.” [[83]

Figure 19: Detection of BASP using NIR
NIR-SERS signal of bacteriophage in close
association with AuNP and S1MP. Reproduced from [83] with permission from The Royal
Society of Chemistry.
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3.2.5

Heating efficiency of BASP
“We
We also investigated the NIR photothermal conversion property
proper of BASP in

deionized water. When irradiated by a NIR laser the temperature in BASP increased by 10°C
from room temperature within 10min while the AuNP did not heat up significantly (Figure
20). The agglomerations of AuNP seen in BASP absorbed NIR photons from lasers resulting
in temperature increase. This heat generation triggered by NIR laser irradiation could
potentially be used for thermal ablation.
ablation.” [83]

BASP
Figure 20: Temperature as a function of NIR laser exposure time of AuNP and BASP.
Reproduced from [83] with permission from The Royal Society of Chemistry.
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3.3

Loading efficiency of BASP

3.3.1

Superparamagnetic iron oxide nanoparticles
“Payload carrying capacity is another important consideration when designing

nanovectors [59; 120]. In MSV, S1MP chemically modified on their surface have a
significantly lower loading capacity of S2NP than unmodified S1MP, due to the
unavailability of sufficiently open pores [75]. Here we evaluated the encapsulation efficiency
of BASP by incorporating either amine functionalized SPION (15nm) or carboxylated QD
(15nm). Post-assembly of AuNP-bacteriophage networks on the S1MP to form BASP retains
the loaded SPION (1.17±0.34ng of iron/µg of silicon, i.e. ~100%) when compared to naked
S1MP (Figure 21A). In contrast, ESTA-S1MP showed 70% lower loading (0.33ng/µg of
silicon) similar to previously published study [75]. This demonstrates the ability of BASP to
maintain the loading efficiency of S1MP while coupling targeted bacteriophage to their
surface. This simple technique of coupling the targeting moiety to the vector enables both
targeting as well as efficient payload delivery. NMR relaxometry data also corresponded to
the loading efficiency, with SPION loaded S1MP exhibiting the shortest transverse relaxation
time as shown in previous work.[78] Correspondingly, the r2 relaxivity (normalized to iron
oxide concentration) of the SPION loaded BASP (162.09mM-1s-1) was half that of SPION
loaded S1MP (258.75mM-1s-1) while that of SPION loaded ESTA-S1MP was significantly
lower (98.63mM-1s-1) (Figure 21B). Conversely, the T2 relaxation times were short for
SPION loaded S1MP and BASP (Figure 21C). The relaxation time of BASP (68.31msec)
was almost twice as long as that of S1MP (39msec) but about 5 times shorter than that of
ESTA-S1MP (354.4msec). These data show that BASP loaded with SPION maintain their
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ability of exhibiting transverse relaxation and hence may be used for magnetic imaging
applications.” [83]

Figure 21: Loading of SPION into BASP. (A) Iron content analysis in S1MP, BASP and
ESTA-S1MP following loading of SPION using the wet incipient method as quantified by
ICP-OES; (B) Comparison of transverse relaxivity, r2 and (C) relaxation times, T2, of
SPION loaded particles. Reproduced from [83] with permission from The Royal Society of
Chemistry.
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3.3.2

Quantum dots
“Next we considered if loaded S2NP were closely associated with S1MP pores or

were released from S1MP during BASP formation. QD loading into S1MP and BASP was
comparable with 4.5±0.45ng of cadmium loaded in 1.5x108 silicon particles in both naked
S1MP and BASP suggesting that QD were not lost during BASP formation. To determine if
the QD escaped out of the S1MP and were trapped in the AuNP-bacteriophage networks, we
visualized the systems using fluorescence microscopy. We would expect unassociated QD
(Figure 22, green) to bind non-specifically to the AuNP-bacteriophage [121]. However, we
observed specific localization of the QD (yellow due to co-localization) with S1MP (Figure
22, red) and an absence of any non-specific staining outside the S1MP. AuNP-bacteriophage
networks incubated with QD served as controls. We observed non-specific labeling of
bacteriophage fibers (green) interspersed with AuNP (red dots).” [83]

62

Figure 22: Loading of quantum dots into BASP. Fluorescence microscopic images of QD
(green) loaded S1MP and BASP (red) showing S1MP colocalization with QD (yellow). In a
control experiment, free QD nonspecifically bound to AuNP-bacteriophage networks (arrow
heads) enable the visualization of the bacteriophage fibers (green) while the AuNP appear as
red dots. Reproduced from [83] with permission from The Royal Society of Chemistry.
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3.3.3

BSA-FITC loading
The macromolecule entrapment efficiency was measured by using a model protein

molecule, fluorescently labeled albumin, and was determined to be highly efficient at 8590%. We used this compound to mimic the loading of the cytotoxic nanodrug, Abraxane®
(albumin bound paclitaxel). Since BSA-FITC is a negatively-charged molecule, we loaded it
into S1MP(+). It can be seen in Figure 14, that the loading process reverted the zeta potential
of S1MP(+) from ~10mV to -30mV demonstrating high efficiency of encapsulation of the
protein model.

3.4

Biodegradation of BASP

3.4.1

In vitro degradation
“Degradation of the drug delivery system in biological fluids is an important

characteristic that determines drug release kinetics as well as biocompatibility of the vector.
We evaluated the degradation kinetics of BASP in simulated in vivo conditions such as 100%
FBS at 37°C under constant motion. SEM micrographs (Figure 23A) and ICP-OES analysis
(Figure 23B) show that the presence of AuNP-bacteriophage networks on S1MP in BASP
does not affect the degradation kinetics of S1MP.

Quantification of the percentage silicon

release by ICP-OES showed complete degradation of both S1MP and BASP within 24h,
consistent with previously published work.[62] Although the degradation profile of BASP
was not different from naked S1MP, the adhesion of serum proteins on particles was
significantly decreased in BASP as seen by the open pores in BASP in contrast to the
covered appearance of the naked S1MP (Figure 23A). This could potentially translate into
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the reduction of opsonization and hence non
non-specific
specific uptake of particles by cells under in
vivo conditions (data not shown).
shown).” [83]

Figure 23: Time dependent degradation of S1MP and BASP in 100% FBS.
FBS (A) SEM
micrographs showing the pattern of degradation of the porous silicon particles over time
(Scale bar = 500nm); (B) ICP
ICP-OES
OES quantification of the degradation profile expressed as a
percentage of total silicon content released from S1MP over time. Reproduced
produced from [83]
with permission from The Royal Society of Chemistry
Chemistry.
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3.4.2

In vivo integrity
“Since the BASP is not a chemically conjugated assembly and is based on

electrostatic interactions, which can be impaired in complex biological fluids (e.g. blood), it
was important to verify the integrity of the systems following in vivo intravenous
administration. We administered CRKL targeted BASP through the tail vein to orthotopic
breast tumor bearing mice and analyzed tumor and liver tissue sections for the integrity of the
systems in vivo. Tumor tissue from mice injected with BASP containing fluorescently
labeled bacteriophage show co-localization of the bacteriophage (red) and S1MP (Figure
24A). Similarly, immunohistochemistry staining for bacteriophage (Figure 24B, brown) in
tumor tissue shows specific association with S1MP. Thus, we can infer that there is a close
association of the bacteriophage and S1MP even after intravenous administration.
Hyperspectral imaging provides unique reflectance spectral analysis of materials. Combined
with dark field microscopy (Figure 24C(i)), hyperspectral imaging was used to identify the
location of BASP. Once the particles were identified, spectra from different pixels on the
particles were collected and grouped into libraries (S1MP and AuNP) (Figure 24C(ii))
according to the shape of the spectra. Mapping these libraries to the image of liver tissues
shows co-localization of the silicon spectra and AuNP spectra (Figure 24C(iii)). The spectra
collected for AuNP show a peak at approximately 650nm, which correlates with the red shift
in the UV-Vis absorbance of BASP. These spectra based mapping confirm proximity of
AuNP and S1MP and thus, the integrity of BASP.” [83]
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Figure 24: In vivo integrity of BASP. Mice bearing EF43.fgf4 mammary allografts were
injected intravenously with BASP. After a 4h circulation time, the animals were sacrificed
and the tumor and liver were harvested and processed for histological analysis. (A)
Fluorescence microscopy and (B) Immunohistochemistry analyses for bacteriophage show
that the bacteriophage remains associated with S1MP and the assembly is not impaired in the
circulation; (C) Hyperspectral images of the liver show superimposed spectral mapping of
silicon and AuNP also confirming the close association of the AuNP and S1MP in the BASP.
Reproduced from [83] with permission from The Royal Society of Chemistry.
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3.5

In vitro targeting efficiency of BASP
BASP are designed to enhance the targeting of S1MP to the tumor. We evaluated the

specificity of binding of CRKL targeted BASP to breast cancer and endothelial cell lines
under static and simulated flow conditions using various microscopic techniques and flow
cytometry.
3.5.1

Static conditions
Figure 25 shows flow cytometry data of HUVEC and HMVEC incubated with S1MP,

non-targeted fd-tet BASP and CRKL targeted BASP. It was observed that endothelial cells
uptake silicon particles non-specifically. There was no statistical significance in the amount
of CRKL targeted BASP uptake vs fd-tet BASP or S1MP uptake in both cell types.

68

conditions Flow
Figure 25: Association of BASP with cells in vitro under static conditions.
cytometric data showing the percentage of endothelial cells associated with BASP; (A)
HUVEC and (B) HMVEC.
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We also analyzed the mode of intracellular uptake by confocal and electron
microscopy (Figure 26). MCF7 cells expressing the highest level of CRKL among the cell
lines tested were used for these experiments. Confocal images demonstrate that CRKL
targeted BASP are associated significantly more than the control groups to MCF7 cells. SEM
micrographs show that after 6h of incubation some of the naked S1MP and control fd-tet
BASP were associated with the cell surface. No internalization of S1MP by the breast cancer
cell was observed in these experiments. In contrast, CRKL targeted BASP were internalized
by breast cancer cells, indicating the specificity of uptake in the case of CRKL targeted
systems. The timeline of internalization is significantly longer than in previous studies
performed on endothelial cells where the cells start internalizing untargeted S1MP within 15
min [115; 122]. This could be explained by the fact that the cells used in this study are of
epithelial origin and are not considered as professional phagocytes.
TEM has shown that the CRKL targeted BASP appear in a perinuclear
vacuole/phagocytic vesicle. The system appears intact with AuNP surrounding S1MP
hemispherical structure. This observation is important in light of the diagnostic potential of
the system as the close proximity of AuNP and S1MP is essential for their detection using
imaging techniques such as CT or NIR-SERS.
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Figure 26: Association and internalization of BASP in MCF7 cells. (A) Confocal
microscopy images showing enhanced association of CRKL targeted BASP (circles)
compared to non-targeted controls (arrowheads). Green – S1MP, Red – Bacteriophage, Blue
– Nucleus; (B) Scanning electron micrographs showing higher number of CRKL targeted
BASP associated/cell when compared to the other two particle types; (C) Transmission
electron micrograph showing perinuclear localization of CRKL targeted BASP.

3.5.2

Effect of shear stress
Particle margination and specific adhesion under shear stress was studied using

Bioflux microfluidic channel plates, traditionally used for leukocyte adhesion and rolling
analysis and platelet aggregation [123]. A schematic representation of the setup is shown in
Figure 27A. It is comprised of a Bioflux 48 well interface, an inverted fluorescence
microscope with a heated biological chamber and Bioflux 200 controller. The hydrodynamic
conditions in the channel are controlled by the pneumatic pressure applied in the inlet and
outlet wells of the channels. Figure 27B compares the number of particles adhering to cell
monolayers in the presence and absence of endothelial cell activation at wall shear rates (S)
of 10 s-1 (shear rate in tumor microvasculature) and 100s-1(shear rate in normal capillaries)
[124; 125]. In contrast to the results in static conditions, it was observed that the number of
CRKL targeted BASP adhering to both types of cells, HUVEC and HMVEC were
significantly higher than fd-tet non-targeted or S1MP themselves at low shear rates of 10s-1.
This difference is even more prominent (2-fold) in the case of HMVEC (microvasculature
cells) when compared to HUVEC (normal endothelial cells).
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As expected, at 100s-1,

corresponding to shear rates in the normal microvasculature, the number of particles
part
adhering
to the cells was significantly reduced regardless of the activation condition of the cells or the
targeting ability of the particles.

Figure 27: Effect of shear stress on the adhesion of CRKL targeted BASP to endothelial
cells. (A) Schematic diagram of the set up showing Bioflux 200 – 48 well flow chamber with
dimensions of the viewing channel and (B) Quantitative measurement of the number of
particles adhered to endothelial cells after a flow for 1h at 10 and 100 s-1 shear rates.
rate
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3.6

In vivo targeting efficiency
To evaluate the tumor accumulation of BASP, 109 1.6µm hemispherical particles

(S1MP, fd-tet BASP or CRKL targeted BASP) were injected via the tail vein into mice
bearing orthotopic EF43.fgf4 tumors. Mice injected with PBS served as negative controls.
The animals were sacrificed 4h after injection and the tumor was harvested for silicon
content analysis by ICP-OES. Figure 28A shows the silicon content of S1MP, fd-tet BASP
and CRKL targeted BASP in the tumor. The CRKL targeted BASP showed upto a 3 fold
higher accumulation in the tumor tissue when compared to S1MP alone.
Similar experiments using fluorescently labeled 1x0.4µm discoidal particles
(108/mouse) were conducted and analyzed using intravital microscopy. Figure 28B shows
representative images of particle accumulation in the tumor 1h after injection. The
accumulation seen was mainly within the first few minutes, after which it leveled off. The
number of particles accumulated in the tumor of mice injected with CRKL targeted BASP
was almost 4 fold higher than the number of particles that accumulated in the other 2
categories (Figure 28C).
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Figure 28: BASP accumulation in breast tumor models. (A) Silicon content in different
tissues as measured by ICP--OES;
OES; (B) Confocal images of tumor tissue showing enhanced
particle (red marked by arrows
arrows)) accumulation in the CRKL targeted BASP injected mice and
(C) Semiquantitative
miquantitative analysis of the number of particles accumulated in the tumor as
calculated from images captured at the end of the experiment.
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The speeds of particles (1x0.4µm discoidal) injected during the intravital microscopic
analysis were measured post acquisition using 2D tracking module in NIS elements software.
The speeds of particles were orders of magnitude different for each case. The CRKL targeted
BASP travelled at speeds of about 10µm/s, while the fd
fd-tet non-targeted
targeted BASP were about
100µm/s and S1MP were the fa
fastest at about 600µm/s (Figure 29).

Figure 29: Speed of particles flowing through the tumor vasculature as measured using
2D tracking module in NIS elements
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3.7

Therapeutic efficacy
EF43.fgf4 tumor bearing mice.
Figure 30 shows the antitumor response of BASP in EF43.

Mice were administered Abx, S1MP
S1MP-Abx, fd-tet BASP-Abx or CRKL targeted BASP-Abx
BASP
(75mg/kg) twice a week.. The Abx and S1MP
S1MP-Abx
Abx treated mice showed marked increase in
tumor size (mean final tumor volume 1.1cm3), while CRKL targeted BASP-Abx
Abx treated mice
showed minimal increase (mean final tumor vvolume 0.4 cm3).

Figure 30: Therapeutic efficiency of Abraxane loaded BASP. Tumor size as a function of
time following treatment with Abx, S1MP Abx or CRKL targeted BASP Abx.
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3.8

CRKL as a soluble biomarker
As mentioned earlier, a recent study showed that intracellular CRKL was secreted

into the extracellular milieu in prostate cancer in vivo models (Mintz et al). Our results also
confirmed the presence of CRKL on breast cancer cell lines as well as on endothelial cell
lines. Based on these, we proposed that the “secreted” CRKL could be detected in both cell
culture supernatants as well as the blood. For this purpose, we tested for the presence of
soluble CRKL in cell culture supernatants, plasma from tumor bearing mice as well as
plasma from clinical breast cancer patients using ELISA.
3.8.1

Evaluation of soluble CRKL in in vitro and in vivo samples
Conditioned media from cell culture supernatants and serum from breast tumor

bearing mice were analyzed by ELISA for secreted CRKL. CM from human breast cancer
cell line, SUM159, showed over a 20 fold higher CRKL concentration than that from normal
breast epithelial cell line MCF10A (545±7 vs 26±5pg/mL, respectively) (Figure 31A). Mean
serum levels of secreted CRKL from mice bearing human derived breast tumors were also
significantly higher than control mice. In particular, mice grafted with patient derived tumors
had about 13 fold higher serum levels of CRKL than control mice (486±130 vs
37±21pg/mL), comparable to the results from in vitro studies (Figure 31B).
3.8.2

Evaluation of soluble CRKL in clinical samples
Soluble CRKL in sera from 29 breast cancer patients and 10 normal donors were

measured by ELISA. The median CRKL concentrations in breast cancer patients’ sera were
more than 1.4 fold higher than in healthy donors (4400±2560 vs 1860±1840 pg/mL,
respectively, p<0.05). Patients with advanced clinical disease, i.e. stage 3 and 4, exhibited a
2.8 fold (5300±2300pg/mL, p<0.005) increase in the serum CRKL concentration in
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comparison to healthy donors (Figure 31C). Serum levels of CRKL were elevated from the
median value in more than 90% of patients with advanced disease (T3 and T4) and in 100%
of patients with metastatic disease. The sera from patients (n=4) who had not undergone any
treatment had higher values than those patients who were undergoing treatment (5800±2000
vs 3600±2700pg/mL, respectively, p= 0.13).
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Figure 31: Assessment of secreted CRKL levels in in vitro, in vivo and clinical samples.
samples
The CRKL concentration (CCRKL) was measured in (A) cell supernatant (B) serum from mice
bearing patient derived breast tumor xenografts and (C) serum from breast cancer patients
using ELISA.
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CHAPTER 4: DISCUSSION

Nanovectors are increasingly used as therapeutic and imaging contrast agents in
cancer due to their ability to bypass biobarriers and selectively accumulate in the tumor site
[126]. An array of nanovectors has been developed with different features and functionalities
over the last few years. While tumor-specific homing of the first nanoparticles took
advantage of the disorganized and leaky vasculature of tumors and relied on passive
accumulation due to the EPR effect, later nanovectors included more active targeting
techniques such as conjugation of molecular recognition moieties, externally guided
accumulation by magnetic focusing, etc. The addition of tumor targeting moieties onto the
first generation nanovectors has its share of unpredictability depending on the affinity of the
moiety to its target. If the affinity is very high, then the nanovectors bind very well to the
cells that it first comes in contact with, such as the endothelium thereby limiting their ability
to extravasate into the tumor [12]. It is not feasible for a single class of nanovectors to
bypass all the sequential biological barriers and reach the tumor in significant quantities,
irrespective of their geometry and targeting specificity. A third generation of nanovectors has
been proposed that is designed to overcome the time-sequential biobarriers and deliver
multiple payloads to the tumor specifically. These “multistage” nanovectors are an assembly
of nanovectors nested within each other, each with unique functions [72].
Physical characteristics, such as geometry of nanovectors have been recognized as
important parameters that dictate their interaction with biological systems both at the cellular
and vascular level [60; 127; 128]. Though size of nanovectors itself does not affect
phagocytosis significantly, the shape has a great impact on their uptake by cells. This was
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studied in macrophages, where, ellipsoidal particles were compared to spherical particles.
Depending on the direction of interaction of ellipsoidal nanovectors and cells, a differential
uptake was noticed. On the other hand, phagocytosis of spherical particle were mostly
uniform due to its symmetry [129]. Vascular interactions have also been linked to size,
shape and density of particles mathematically and experimentally. Under shear flow,
discoidal particles exhibited higher adhesion to endothelial cells than spherical particles [127;
130]. Based on these mathematical models, our lab designed non-spherical porous silicon
microparticles that serve as first stage particles (S1MP) in multistage vectors. The S1MP are
designed to facilitate their preferential concentration on tumor vasculature and the encasing
of second stage nanoparticles (S2NP). The S2NP which in turn carry therapeutic or imaging
agents are released into the tumor.
The S1MP are fabricated using photolithography and can be tailored to produce
various geometries of particles, ranging from discoidal to hemispherical to cylindrical. The
pore size and porosity can be tuned by electrochemical etching according to requirements.
The pore sizes range from 5nm to 120nm in diameter [69]. Various studies with these
particles have been conducted. S2NP, such as SPION [78], quantum dots [59], gadolinium
nanotubes [80], paclitaxel containing micelles [79], liposomes [77] and hollow gold
nanoshells [81] have been loaded into these particles. The surface of the S1MP has been
decorated with peptides [74], thioaptamers [75], biomimetic leukocyte membrane [76] and
agarose [24] to either facilitate tumor homing or lysosomal escape or avoid immune
recognition.
While the above studies have demonstrated the successful loading and conjugation of
targeting moieties independently, combining the two efficiently have been a challenge. The
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design of nanovectors governs their accumulation at a specified site. The design parameters
include size [131], shape [132; 133; 134], surface charge [135; 136; 137] and deformability
[138]. Another important parameter is the surface decoration with targeting ligands specific
to the disease microenvironment [139; 140].Typically, the addition of molecular targeting
ligands on nanovector surfaces involve covalent conjugation chemistry that may impair the
targeting ability of the biological entities as well as reduce the volume of pores available for
loading active substances, in the case of porous drug carriers.
In this study, we demonstrate a simple method to immobilize molecularly targeted
bacteriophage

on

S1MP

without

compromising

its

payload

carrying

potential.

Immobilization of bacteriophage on various surfaces has been performed for use as
antibacterial

agents/surfaces

[141].

However

most

of

these

reports

use

either

covalent/chemical conjugation techniques or genetic modifications for the immobilization.
These processes, as described above can be detrimental to the drug carrier or can be
complicated and time consuming. We proposed the use of electrostatic interactions to
assemble BASP, by co-incubation of S1MP, bacteriophage and AuNP. Since the formation
of these electrostatic interactions is spontaneous, we were able to load the S1MP with S2NP
and instantaneously cover with the AuNP–bacteriophage networks, thus avoiding loss of
loaded S2NP.
Among the physical parameters involved in designing BASP, we studied the effect of
shape, size, surface potential and porosity on the BASP formation. It was observed that shape
and size of S1MP did not have an effect on the formation of BASP. However, the
association of AuNP

with S1MP was evidently better with positively charged, porous

particles than their association with non-porous silica beads or negatively charged particles.
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The porosity of particles provides an increased surface area with more sites for the
interaction of the bacteriophage with the particles. This observation that porosity of S1MP
enhances the adhesion of AuNP–bacteriophage networks is in agreement with previous
studies on the effect of particle porosity on the efficiency of surface adsorption [142].
While positively charged nanovectors have greater efficiency in cell membrane
penetration and internalization, compared to negatively charged particles, they also elicit
more immune responses when in circulation [143]. On the other hand, negatively charged
particles are better at avoiding recognition by the immune system. Our observation that
positively charged S1MP form BASP more efficiently also has the advantage that the final
BASP formed has a net negative charge and thereby could potentially avoid recognition by
the immune system. Further, the negative charge might help in avoiding non-specific
internalization of the BASP, allowing them to release S2NP into the tumor
microenvironment.
The formation of BASP is characterized by a red shift in the UV-Vis absorbance of
AuNP from around 530nm to 710nm explained by dipole-dipole interactions between AuNP
when the interparticle distance becomes lesser than its diameter [109]. However, this red
shift occurs at very specific ratios of bacteriophage and AuNP. At higher ratios of
bacteriophage to AuNP, the placement of AuNP on bacteriophage is sufficiently large to
avoid dipole-dipole interactions. In contrast, at lower ratios, the concentration of
bacteriophage is very dilute and hence, majority of the AuNP are still in colloidal form and
do not interact with each other. Thus, it is important to achieve a delicate balance in the
relative concentrations of phage and AuNP during formation of the networks.
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Red-shift in UV-Vis absorbance corresponds to an increase in the NIR absorbance.
This can be used to advantage because most deep tissue imaging utilizes this NIR window
(650-900nm), where hemoglobin is transparent [144], to discern function, localization,
affinity and fate of nanovectors through their innate scattering properties [145]. Here we
demonstrate that non-invasive, longitudinal imaging techniques such as NIR-SERS can be
used to provide critical information at the molecular scale in real-time. Fingerprints of BASP,
that appear when bacteriophage and S1MP are in close association with AuNP, can be used
as signal reporters for monitoring the formation and presence of BASP. These photonic
properties of BASP originating from the quantum confinement of AuNP in BASP are tunable
based on the design of the system and offer a direct ability to assess their interaction within
biological systems, providing diagnostic capability [83].
As discussed above, one of the major requirements of a good nanovector is high
payload carrying capacity. However chemical conjugation of targeting moieties frequently
hampers this feature [75]. Here, we demonstrated that S1MP retain their payload carrying
capacity even after the incubation with AuNP-bacteriophage networks to form BASP. Solid
nanoparticles such as SPION and quantum dots as well as protein molecules such as BSAFITC (model drug molecule) were loaded into the S1MP successfully. This simple technique
of coupling the targeting moiety to the nanovector enables both targeting as well as efficient
payload delivery.
Having shown the efficient payload encapsulation, we studied the targeting ability of
BASP. In our study, we hypothesized that an intracellular adaptor protein, CRKL, secreted
by tumor cells into the microenvironment would bind to the extracellular domain of integrins
on both tumor cells as well as endothelial cells’ surface. We proposed that this extracellular
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CRKL can serve as a good target for homing nanovectors to the tumor site. To confirm our
hypothesis, we evaluated the surface localization of CRKL in endothelial cells and breast
cancer cells. While only a small percentage of endothelial cells were positive for surface
CRKL, incubation with cancer cell CM, increased the surface localization of CRKL. We also
showed that CRKL is secreted from tumor cells into the cell culture supernatant. Thus, the
enhanced CRKL in CM treated endothelial cells could be the soluble CRKL secreted by
cancer cells. Further, in vivo allografts showed colocalization of CRKL in endothelial cells,
suggesting that CRKL in these endothelial cells can act as a target for nanovectors. We also
detected an increased surface-bound fraction of CRKL in various breast cancer cell lines
when compared to non-cancerous epithelial cell lines. Immunofluorescence staining of breast
cancer cell lines revealed CRKL on both the cell surface as well as in the intracellular
compartments.
In accordance with in vitro studies, CRKL was over-expressed in tumor sections
(Figure 11). Although immunohistochemical staining is not specific for surface-bound
CRKL, it is in agreement with previously published data that CRKL is over-expressed in
various tumor models, including gastric carcinomas [95], head and neck squamous cell
carcinomas [146] and lung carcinomas [97]. Recent work by Zhao et al has shown that
CRKL is over-expressed in 37% of breast cancer samples studied and was correlated with
progression and malignant proliferation [100]. Our results provide further evidence that
tissue expression of CRKL can serve as a potential tissue biomarker for breast tumors.
Moreover, we anticipate that in addition to the use of CRKL as a molecular target,
membranal presence of the protein on the surface of endothelial and tumor cells can

86

serve as selective target to direct nanoparticle based therapeutics and diagnostics to the
tumor.
Thus, we used extracellular CRKL targeted, genetically engineered bacteriophage
expressing a peptide sequence, YRCTLNSPFFWEDMTHECHA, homologous to the plexinsemaphorin integrin domain of β1 integrins in the formation of BASP. This phage has been
shown to be as effective at targeting prostate tumor cells as the more commonly used RGD
peptide [92]. Here we tested the efficiency of CRKL targeted phage to bind endothelial cells.
CRKL targeted BASP were compared to S1MP and fd-tet non-targeted BASP. Our data
showed that there was no significant differences in the association of CRKL targeted BASP
to endothelial cells when compared to the other two particle types in vitro under static
conditions. This is in correlation with data previous published on endothelial cells [115].
Endothelial cells act like professional phagocytes and uptake nanoparticles non-specifically.
We also tested the efficiency of uptake of CRKL targeted BASP in breast cancer cell line,
MCF7, that has a significant amount of CRKL on its surface. In this case, we could see a
significant enhancement in the association/uptake of CRKL targeted BASP through specific,
probably receptor mediated, interactions with the epithelial cell line as evidenced by the
presence of BASP inside a vesicle when internalized (Figure 26C).
In contrast to targeting experiments under static conditions, our results from
experiments conducted under shear stresses, capitulate better the observed behavior in vivo.
For example, we saw that the number of CRKL targeted BASP associated with endothelial
cells under low shear stress, such as that seen in tumor microcirculation, was twice as much
as non-targeted fd-tet BASP or S1MP. This is due to the formation of strong interactions
between CRKL on the surface of endothelial cells and the peptide expressed on
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bacteriophage coat proteins. In the case of S1MP and fd-tet BASP, although they probably
experience similar hemodynamic flow conditions, they do not form strong bonds by means of
receptor-ligand interactions. Thus, the hemodynamic forces dislodge the particles before they
can form a firm bond with the endothelial cells. As a result, more CRKL targeted BASP
remain adhered to the cells than non-targeted particles. On the contrary, at higher shear rates
of 100s-1(healthy microvasculature) the forces are much higher and thus the likelihood of
particle adhesion is reduced. At these shear rates, the presence of targeting moieties on the
particle surface did not make a significant difference in the binding of particles to endothelial
cells, thereby suggesting that addition of targeting moiety onto the S1MP enhances the
binding of particles to only tumor microvasculature and not to healthy microvasculature.
When evaluating the systems in vivo, we observed that the changes were significantly
enhanced when compared to in vitro conditions. For example, the number of CRKL targeted
BASP bound to the tumor in in vivo allografts was 4-fold higher than non-targeted particles.
Also, the speeds of particles were orders of magnitude different for each case. The CRKL
targeted particles travelled at speeds of about 10µm/s, while the fd-tet BASP were about
100µm/s and the S1MP were the fastest at about 600µm/s. This apparent difference between
the in vitro and in vivo studies could be attributed to the differences in conditions. For
example, in vivo flow involves not only specific shear rates, as is considered in in vitro
studies, but also has very tortuous vasculature and whole blood containing multicellular
components, all of which can affect the hemodynamics of blood flow.
Finally, we evaluated if this targeted system could efficiently carry therapeutics to the
tumor site. For this, we injected tumor bearing mice with Abraxane loaded BASP and
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compared their effect to either Abraxane itself or Abraxane loaded S1MP. We found that the
targeting of the BASP significantly enhanced their therapeutic efficiency.
CRKL as a serum biomarker
In breast tumors, the majority of clinically used biomarkers are proteins overexpressed in tissue, which can be detected histologically in specimens from biopsies or
following tumor resection. Their expression prescribes various treatment settings and is
correlated to disease prognosis [147], particularly in the early disease stages. One of such
biomarkers, c-erbB2, led to the discovery of trastuzumab [148]. However, the necessitation
of invasive biopsies is a drawback that may be addressed by the detection of soluble
biomarkers in body fluids. Overexpressed and secreted proteins from cancer cells, detected in
the sera of cancer patients, are easy to collect and have been used clinically as diagnostic and
prognostic markers for cancers [149]. A few examples of secreted proteins used for cancer
diagnosis include prostate specific antigen for prostate cancer [150], carcinoembryonic
antigen CA125 for ovarian cancer [151] and cytokine colony stimulating factor-1 (CSF-1)
[152] for endometrial carcinoma. A few soluble biomarkers for breast cancers include CA
15.3 and CA 27.59 and vascular endothelial growth factor (VEGF) which have shown to be
of prognostic value and are being evaluated in conjunction with diagnostic imaging to
monitor metastatic diseases during the course of therapy [147].
In this study, we propose that CRKL, generally considered as an intracellular protein,
can serve as a soluble biomarker for breast tumors. It is generally agreed that intracellular
signaling of CRKL is involved in tumor progression of various tumor types, however, the
role of soluble (secreted) fraction of CRKL have not been explored. For this purpose, we
analyzed in vitro, in vivo and clinical samples to evaluate if the soluble fractions of CRKL
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can be detected in cell culture media and blood serum. Our results showing significantly
higher levels of soluble CRKL in serum from breast tumor xenograft bearing mice and breast
tumor patients to healthy donors, suggest the use of CRKL as a soluble biomarker. The most
widely used clinical breast cancer biomarker, CA 15.3, serves as a prognostic marker, to
monitor response of breast cancer to treatment or detect early relapse [153]. However, CA
15-3 is elevated in only 3% of patients with localized early stage cancer and upto 70% of
patients with metastatic disease [154]. In our study, we found that 100% of patients with
metastatic disease have elevated serum levels of CRKL. Thus, soluble CRKL might serve as
a stronger biomarker for predicting metastasis. Further, among patients analyzed in this
study, four had not undergone treatment and had mean values 1.6 fold higher than the rest of
the patients (n=25) who were undergoing treatment. Albeit the small sample size, this clear
trend with a p-value of 0.13, suggests that CRKL levels might also be useful in monitoring
treatment of breast cancer and requires further evaluation in larger sample size or progressive
clinical studies.

CONCLUSIONS AND FUTURE DIRECTIONS

In this study we report a strategy for non-covalent attachment of targeting entities to
porous silicon particle surfaces, which enables independent control over the loading of
actives into the porous structure of the particles and their targeting to elements in the tumor
microenvironment. The attachment of AuNP-bacteriophage networks on the S1MP surface
does not impair the loading capacity of naked S1MP. The resulting BASP are biodegradable
in serum and maintain their integrity while injected intravenously. This shows that
electrostatic interactions of components in the system are stable under constant motion as
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well as in vivo. We demonstrated that extracellular CRKL (traditionally thought of to be an
intracellular protein) served as a very good target for efficient tumor directed accumulation
of BASP and subsequently improved therapeutic effect on breast cancer allograft models.
We have also revealed that high levels of secreted CRKL can be detected in the
plasma of breast tumor bearing mice and breast cancer patients. To the best of our
knowledge, this is the first report about the possibility to detect soluble fractions of CRKL in
body fluids from cancer patients. The results of our study suggest that CRKL can be used as
a soluble serum biomarker in breast cancer patients especially in the advanced disease stages.
The BASP has more applications that haven’t been studied to its full potential, for
example, the applications related to the optical properties of AuNP in BASP, such as NIRSERS imaging and detection in vivo and thermal ablation of tumors using NIR lasers. These
BASP also present multiple opportunities for future research and improvement. The
bacteriophage in BASP can be easily replaced with bacteriophage displaying any other
targeting peptide of choice. Based on the targeting moieties chosen, BASP can also be
evaluated for use in inflammatory conditions and cardiovascular diseases. Further, the S2NP
can themselves be decorated with a targeting moiety or other surface decorations that can be
used to overcome additional barriers, such as facilitation of lysosomal escape or subcellular
organelle targeting, thereby providing a “two-fold” targeting of the nanovector, i.e. tumor
targeting by the S1MP and cellular targeting by the S2NP.
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